<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000193.pub3" GROUP_ID="LIVER" ID="676099090618360120" MERGED_FROM="" MODIFIED="2012-01-17 11:06:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="02A" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="13.0">
<COVER_SHEET MODIFIED="2012-01-17 10:51:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE>Somatostatin analogues for acute bleeding oesophageal varices</TITLE>
<CONTACT>
<PERSON ID="6571" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Gøtzsche</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>pcg@cochrane.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT>
<ORGANISATION>Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7112</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7007</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-01-17 10:51:51 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="6571" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Gøtzsche</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>pcg@cochrane.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT>
<ORGANISATION>Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7112</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7007</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6454" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Asbjørn</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hróbjartsson</LAST_NAME>
<SUFFIX/>
<POSITION>Senior researcher</POSITION>
<EMAIL_1>ah@cochrane.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT>
<ORGANISATION>Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9,3343</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7145</PHONE_1>
<PHONE_2>+45 3332 5834</PHONE_2>
<FAX_1>+45 3545 7007</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2011-11-25 14:06:29 +0100" MODIFIED_BY="Sarah Louise Klingenberg">
<UP_TO_DATE>
<DATE DAY="14" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="11" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="6" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1997"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-11 10:20:17 +0100" MODIFIED_BY="dimitrinka nikolova">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-01-11 10:20:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="11" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>Updated, no new trials identified.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2012-01-11 10:20:14 +0100" MODIFIED_BY="Sarah L Klingenberg">
<DATE DAY="25" MONTH="11" YEAR="2011"/>
<DESCRIPTION>
<P>No further trials are likely to be performed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-05 14:10:28 +0200" MODIFIED_BY="dimitrinka nikolova"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Rigshospitalet</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-01-17 11:04:24 +0100" MODIFIED_BY="dimitrinka nikolova">
<SUMMARY>
<TITLE>Somatostatin analogues for acute bleeding oesophageal varices</TITLE>
<SUMMARY_BODY>
<P>Cirrhosis of the liver is a chronic, progressing disease that is most commonly caused by excessive use of alcohol or by hepatitis C infection. The liver tissue is replaced by connective tissue, which leads to loss of liver function. People with cirrhosis of the liver may develop varicose veins (enlarged blood vessels or varices) in the gullet. Bleeding varices can be life-threatening. The hormone somatostatin, or similar drugs like octreotide and vapreotide, can be used to try to stop the bleeding. The review of 21 trials (2588 patients) found that the tested drugs did not reduce deaths. There was a small reduction in the need for blood transfusions, corresponding to one half unit of blood saved per patient. It is doubtful whether this effect is worthwhile. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-11-25 14:14:37 +0100" MODIFIED_BY="Sarah L Klingenberg">
<ABS_BACKGROUND>
<P>Somatostatin and its derivatives are sometimes used for emergency treatment of bleeding oesophageal varices in patients with cirrhosis of the liver.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To study whether somatostatin or its analogues improve survival or reduce the need for blood transfusions in patients with bleeding oesophageal varices.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-11-25 14:14:37 +0100" MODIFIED_BY="Sarah L Klingenberg">
<P>PubMed and <I>The Cochrane Library</I> were searched (1 November 2011). Reference lists of publications, contacts with authors.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised trials comparing somatostatin or analogues with placebo or no treatment in patients suspected of acute or recent bleeding from oesophageal varices.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The outcome measures extracted were: mortality, blood transfusions, use of balloon tamponade, initial haemostasis and rebleeding. Intention-to-treat analyses including all randomised patients were conducted if possible; a random-effects analysis was preferred if there was significant heterogeneity between the trials (P &lt; 0.10). The trials were divided in two groups: trials with a low risk of bias, which had concealed allocation of patients and were double-blind, and other trials.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We included 21 trials (2588 patients). The drugs did not reduce mortality significantly (relative risk 0.97, 95% confidence interval (CI) 0.75 to 1.25, for the trials with a low risk of bias, and 0.80, 95% CI 0.63 to 1.01, for the other trials). Units of blood transfused were 0.7 (0.2 to 1.1) less with drugs in the trials with a low risk of bias and 1.5 (0.9 to 2.0) less in the other trials. Number of patients failing initial haemostasis was reduced, relative risk 0.68 (0.54 to 0.87). Number of patients with rebleeding was not significantly reduced for the trials with a low risk of bias, relative risk 0.84 (0.52 to 1.37) while it was substantially reduced in the other trials, relative risk 0.36 (0.19 to 0.68). Use of balloon tamponade was rarely reported. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The need for blood transfusions corresponded to one half unit of blood saved per patient. It is doubtful whether this effect is worthwhile. The findings do not suggest a need for further placebo-controlled trials of the type reviewed here. A large placebo controlled trial enrolling thousands of patients is needed if one wishes to rule out the possibility that a worthwhile effect on mortality might have been overlooked.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-11-29 11:23:29 +0100" MODIFIED_BY="dimitrinka nikolova">
<BACKGROUND>
<P>Somatostatin is an oligopeptide hormone that has reduced portal blood flow or hepatic venous pressure gradient in most experimental studies, both in animals and in man (<LINK REF="REF-Samnegaard-1980" TYPE="REFERENCE">Samnegaard 1980</LINK>; <LINK REF="REF-Hanisch-1992" TYPE="REFERENCE">Hanisch 1992</LINK>; <LINK REF="REF-Cirera-1995" TYPE="REFERENCE">Cirera 1995</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>), while its effect on intraoesophageal pressure is more equivocal (<LINK REF="REF-Greco-1982" TYPE="REFERENCE">Greco 1982</LINK>; <LINK REF="REF-Kleber-1988" TYPE="REFERENCE">Kleber 1988</LINK>; <LINK REF="REF-Hanisch-1992" TYPE="REFERENCE">Hanisch 1992</LINK>; <LINK REF="REF-Nevens-1994" TYPE="REFERENCE">Nevens 1994</LINK>). Octreotide and vapreotide are derivatives of somatostatin that have a much longer half-life than the native hormone but similar properties (<LINK REF="REF-McCormick-1992" TYPE="REFERENCE">McCormick 1992</LINK>; <LINK REF="REF-Albillos-1994" TYPE="REFERENCE">Albillos 1994</LINK>; <LINK REF="REF-Lamberts-1996" TYPE="REFERENCE">Lamberts 1996</LINK>; <LINK REF="STD-Cal_x00e8_s-2001" TYPE="STUDY">Calès 2001</LINK>), apart from the effect on portal pressure of octreotide which is very short-lived, at best (<LINK REF="REF-M_x00f8_ller-1997" TYPE="REFERENCE">Møller 1997</LINK>; <LINK REF="REF-Escorsell-2001" TYPE="REFERENCE">Escorsell 2001</LINK>). </P>
<P>Somatostatin analogues are sometimes used for emergency treatment of bleeding oesophageal varices in patients with cirrhosis of the liver. We reviewed the randomised trials that compared these drugs with placebo or no treatment . The present systematic review is an update of our previous review (<LINK REF="REF-G_x00f8_tzsche-2005" TYPE="REFERENCE">Gøtzsche 2005</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To study whether somatostatin or its analogues improve survival or reduce the number of blood transfusions in patients with suspected or verified acute or recently bleeding oesophageal varices.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-11-29 11:23:29 +0100" MODIFIED_BY="Sarah L Klingenberg">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised trials comparing somatostatin or its analogues with placebo or no treatment, irrespective of language, publication type, or year of publication. Trials where it is clear that the allocation was not concealed were not included. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients suspected of acute or recent bleeding from oesophageal varices. Stable patients in trials studying the effect on rebleeding were not included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Experimental: somatostatin, given intravenously, or analogues, given intravenously or subcutaneously.<BR/>Control: placebo or no treatment. <BR/>Trials that specified that all patients, in addition to the trial drugs, should undergo sclerotherapy or ligation, or other types of co-intervention, were accepted.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-05-20 16:16:06 +0200" MODIFIED_BY="dimitrinka nikolova">
<OL>
<LI>Mortality.</LI>
<LI>Number of blood transfusions.</LI>
<LI>Number with balloon tamponade.</LI>
<LI>Number failing initial haemostasis.</LI>
<LI>Number with rebleeding.</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-11-29 11:22:59 +0100" MODIFIED_BY="Sarah L Klingenberg">
<P>PubMed from 1966 onwards and <I>The Cochrane Library</I> were searched with the terms (somatostatin OR octreotide OR vapreotide OR lanreotide) combined with (varic* OR bleed* OR hemorrhag* OR hematemesis OR melena); date of last searches November 2011. Abstracts from conference proceedings were provided by The Cochrane Hepato-Biliary Group and the group's trial register was searched in January 2008.</P>
<P>We accepted reports in any language, unpublished trials, and trials published only as abstracts in an attempt to minimise the impact of publication bias, although proper assessment of the trials is rarely possible in this difficult area based on summary data alone. We scanned reference lists of trial reports and contacted the authors. Decisions on inclusion of trials were made by the two authors independently; disagreements were settled by discussion.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-11-29 11:23:29 +0100" MODIFIED_BY="Sarah L Klingenberg">
<P>
<B>Data collection</B>
<BR/>We extracted data on type of drug, dosage and duration, number of randomised patients, the randomisation and blinding procedures, exclusions from analysis, deaths, number of blood transfusions and number of patients with balloon tamponade, initial haemostasis, and rebleeding. We contacted the authors when the information was unclear or insufficient. Data extraction was made by the two authors independently; disagreements were settled by discussion.</P>
<P>
<B>Risk of bias</B>
<BR/>The trials were divided in two groups, according to risk of bias. To qualify for the low bias risk group, the allocation of patients to treatment groups had to be concealed and the trials had to be double-blind (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). Blinding was chosen as an additional criterion to the quality of the allocation process, since we and other trialists have observed that decisions to use balloon tamponade or to give transfusions, or whether or not to define a patient as a therapeutic failure could be influenced by knowledge of the treatment assignment (<LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>).</P>
<P>
<B>Statistical methods</B>
<BR/>Intention-to-treat analyses were conducted if possible. A random effects analysis was preferred if there was significant heterogeneity between the trials (P &lt; 0.10). The I<SUP>2</SUP> statistic was used to describe the degree of heterogeneity; it can be interpreted as the proportion of the observed discrepancy in the estimation of the effect, within a group of trials, which cannot be accounted for by random variation (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). For blood transfusions, the standard deviations were quite variable across trials and the distributions were very skewed. Therefore, we checked our calculation of the weighted mean difference by calculating a simple average of the reported number of transfusions, weighted by the sample sizes of the trials (<LINK REF="REF-G_x00f8_tzsche-1989" TYPE="REFERENCE">Gøtzsche 1989</LINK>). As this led to very similar results, we present below only the weighted mean differences. When the authors had reported data at several time points on bleeding control, we chose 48 h whenever possible as this interval was most often used by the authors. Criteria for failing initial haemostasis and for rebleeding were those used by the trial authors, although we and other trialists (<LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>) are aware that the authors' decisions on cut-offs and definitions could have been biased. For mortality, we preferred data at six weeks, if available, since it is clinically relevant and recommended by trialists in this area (<LINK REF="REF-Baveno-II-1996" TYPE="REFERENCE">Baveno II 1996</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-05-20 16:16:33 +0200" MODIFIED_BY="dimitrinka nikolova">
<P>We included 21 trials (average of about 100 patients per trial, range 60-383). Seven trials were funded by industry; ten trials had no information on funding; and four trials were funded by public sources or had no funding (<LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>; <LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>; <LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>). See graphs and Table: 'Characteristics of included studies' for details.</P>
<P>All patients had suspected or verified acute or recent bleeding from oesophageal varices. Endoscopic confirmation prior to randomisation was mentioned in 12 of the trials (<LINK REF="STD-Valenzuela-1989" TYPE="STUDY">Valenzuela 1989</LINK>; <LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK>; <LINK REF="STD-Pauwels-1994" TYPE="STUDY">Pauwels 1994</LINK>; <LINK REF="STD-Besson-1995" TYPE="STUDY">Besson 1995</LINK>; <LINK REF="STD-Sung-1995" TYPE="STUDY">Sung 1995</LINK>; <LINK REF="STD-Shah-1996" TYPE="STUDY">Shah 1996</LINK>; <LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK>; <LINK REF="STD-Farooqi-2000" TYPE="STUDY">Farooqi 2000</LINK>; <LINK REF="STD-Freitas-2000" TYPE="STUDY">Freitas 2000</LINK>; <LINK REF="STD-Zuberi-2000" TYPE="STUDY">Zuberi 2000</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>; <LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>); in an additional study, this occurred for half of the patients (<LINK REF="STD-Burroughs-1990" TYPE="STUDY">Burroughs 1990</LINK>). In the other studies it was either not mentioned or they were of a pragmatic design, mirroring what happens in practice where a definitive diagnosis is not always possible before treatment is started. In 14 studies, most patients underwent sclerotherapy (<LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK>; <LINK REF="STD-Besson-1995" TYPE="STUDY">Besson 1995</LINK>; <LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>; <LINK REF="STD-Shah-1996" TYPE="STUDY">Shah 1996</LINK>; <LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK>; <LINK REF="STD-Signorelli-1996" TYPE="STUDY">Signorelli 1996</LINK>; <LINK REF="STD-Avgerinos-1997" TYPE="STUDY">Avgerinos 1997</LINK>; <LINK REF="STD-Signorelli-1997" TYPE="STUDY">Signorelli 1997</LINK>; <LINK REF="STD-Farooqi-2000" TYPE="STUDY">Farooqi 2000</LINK>; <LINK REF="STD-Freitas-2000" TYPE="STUDY">Freitas 2000</LINK>; <LINK REF="STD-Zuberi-2000" TYPE="STUDY">Zuberi 2000</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>; <LINK REF="STD-Souza-2003" TYPE="STUDY">Souza 2003</LINK>; <LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>) in another, ligation (<LINK REF="STD-Sung-1995" TYPE="STUDY">Sung 1995</LINK>) as part of the trial protocol, and in one trial the patients either underwent sclerotherapy or ligation (<LINK REF="STD-Cal_x00e8_s-2001" TYPE="STUDY">Calès 2001</LINK>).</P>
<P>The dose schedules and length of treatment were quite variable:</P>
<UL>
<LI>somatostatin bolus 250 µg: <LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK> (no subsequent infusion).</LI>
</UL>
<UL>
<LI>somatostatin bolus 100 µg/h and infusion 50 µg/h: <LINK REF="STD-Souza-2003" TYPE="STUDY">Souza 2003</LINK> (3 days).</LI>
</UL>
<UL>
<LI>somatostatin infusion 250 µg/h: <LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK> (24 h for each bleeding episode).</LI>
</UL>
<UL>
<LI>somatostatin bolus 250 µg and infusion 250 µg/h: <LINK REF="STD-Avgerinos-1997" TYPE="STUDY">Avgerinos 1997</LINK> (up to eight bolus injections, infusion for 5 days); <LINK REF="STD-Burroughs-1990" TYPE="STUDY">Burroughs 1990</LINK> (5 days); <LINK REF="STD-Isaac-1994" TYPE="STUDY">Isaac 1994</LINK> (15 h); <LINK REF="STD-Pauwels-1994" TYPE="STUDY">Pauwels 1994</LINK> (till 2 h after bleeding arrest); <LINK REF="STD-Valenzuela-1989" TYPE="STUDY">Valenzuela 1989</LINK> (up to 30 h); <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK> (bolus every 12 h, infusion for 5 days).</LI>
</UL>
<UL>
<LI>somatostatin infusion 3.5 µg/kg/h or octreotide 0.1 mg subcutaneously: <LINK REF="STD-Signorelli-1996" TYPE="STUDY">Signorelli 1996</LINK> (5 days).</LI>
</UL>
<UL>
<LI>octreotide infusion 25 µg/h: <LINK REF="STD-Besson-1995" TYPE="STUDY">Besson 1995</LINK> (5 days); <LINK REF="STD-Freitas-2000" TYPE="STUDY">Freitas 2000</LINK> (48 h); <LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK> (5 days) .</LI>
</UL>
<UL>
<LI>octreotide bolus 50 µg and infusion 25 µg/h: <LINK REF="STD-Signorelli-1997" TYPE="STUDY">Signorelli 1997</LINK> (5 days).</LI>
</UL>
<UL>
<LI>octreotide infusion 50 µg/h: <LINK REF="STD-Burroughs-1996" TYPE="STUDY">Burroughs 1996</LINK> (5 days); <LINK REF="STD-Farooqi-2000" TYPE="STUDY">Farooqi 2000</LINK> (48 h); <LINK REF="STD-Shah-1996" TYPE="STUDY">Shah 1996</LINK> (36 h or 48 h, contrasting information); <LINK REF="STD-Zuberi-2000" TYPE="STUDY">Zuberi 2000</LINK> (5 days).</LI>
</UL>
<UL>
<LI>octreotide bolus 50 µg and infusion 50 µg/h: <LINK REF="STD-Sung-1995" TYPE="STUDY">Sung 1995</LINK> (5 days).</LI>
</UL>
<UL>
<LI>octreotide bolus 50 µg, infusion 50 µg/h for 24 h, and 25 µg/h for another 24 h (<LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>).</LI>
</UL>
<UL>
<LI>vapreotide bolus 50 µg and infusion 50 µg/h: <LINK REF="STD-Cal_x00e8_s-2001" TYPE="STUDY">Calès 2001</LINK> (5 days).</LI>
</UL>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The allocation was concealed and the trial was double-blind in ten trials (<LINK REF="STD-Burroughs-1990" TYPE="STUDY">Burroughs 1990</LINK>; <LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK>; <LINK REF="STD-Besson-1995" TYPE="STUDY">Besson 1995</LINK>; <LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>; <LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK>; <LINK REF="STD-Avgerinos-1997" TYPE="STUDY">Avgerinos 1997</LINK>; <LINK REF="STD-Zuberi-2000" TYPE="STUDY">Zuberi 2000</LINK>; <LINK REF="STD-Cal_x00e8_s-2001" TYPE="STUDY">Calès 2001</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>; <LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>); in addition, blinding during data analysis was used in four trials (<LINK REF="STD-Avgerinos-1997" TYPE="STUDY">Avgerinos 1997</LINK>; <LINK REF="STD-Burroughs-1990" TYPE="STUDY">Burroughs 1990</LINK>; <LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>; <LINK REF="STD-Cal_x00e8_s-2001" TYPE="STUDY">Calès 2001</LINK>). </P>
<P>Eight trials included all or nearly all (&gt; 90%) of the randomised patients in the analysis (<LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK>; <LINK REF="STD-Besson-1995" TYPE="STUDY">Besson 1995</LINK>; <LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>; <LINK REF="STD-Sung-1995" TYPE="STUDY">Sung 1995</LINK>; <LINK REF="STD-Avgerinos-1997" TYPE="STUDY">Avgerinos 1997</LINK>; <LINK REF="STD-Zuberi-2000" TYPE="STUDY">Zuberi 2000</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>; <LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>). In four trials (<LINK REF="STD-Burroughs-1990" TYPE="STUDY">Burroughs 1990</LINK>; <LINK REF="STD-Pauwels-1994" TYPE="STUDY">Pauwels 1994</LINK>; <LINK REF="STD-Burroughs-1996" TYPE="STUDY">Burroughs 1996</LINK>; <LINK REF="STD-Cal_x00e8_s-2001" TYPE="STUDY">Calès 2001</LINK>), some of the randomised patients were excluded because the source of bleeding was judged to be non-variceal. In the remaining trials it was not clear whether there had been additional patients that were not accounted for. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>We included 21 trials (2588 patients). The drugs did not reduce mortality significantly, relative risk (RR) 0.97, 95% confidence interval (CI) 0.75 to 1.25, for the trials with low risk of bias, and 0.80 (95% CI 0.63 to 1.01) for the other trials (see graphs). The result was similar for those trials where active drug was administered for five days, RR 0.90 (95% CI 0.74 to 1.09) for the trials with low risk of bias. </P>
<P>For average number of blood transfusions, the trials with low risk of bias were significantly heterogeneous (P = 0.06, I<SUP>2 </SUP>= 47%). The heterogeneity was caused by two trials (<LINK REF="STD-Burroughs-1990" TYPE="STUDY">Burroughs 1990</LINK>; <LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>) that both reported a median difference of three transfusions but in opposite directions. The average effect for the trials with low risk of bias was 0.7 (95% CI 0.2 to 1.1) units of blood products saved with somatostatin analogues. The result was very similar if the two outliers were excluded, 0.7 units (95% CI 0.4 to 1.0), or if the analysis was restricted to the seven trials with low risk of bias where active drug was administered for five days, 0.8 units (95% CI 0.4 to 1.2). The standard deviations were quite variable across trials and the distributions were very skewed. Even so, all but two trials reported means rather than medians. As just noted, the use of medians in two trials did not have any impact on the meta-analysis, which is supported by the fact that the difference between drug and placebo in three other trials that reported both means and medians were very similar for the two measures of effect (<LINK REF="STD-Besson-1995" TYPE="STUDY">Besson 1995</LINK>; <LINK REF="STD-Villanueva-2001" TYPE="STUDY">Villanueva 2001</LINK>; <LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>). Because of the skewness, it is doubtful whether the best method to combine the trials is to use the weighted mean difference. Reassuringly, however, a simple average of the reported number of transfusions, weighted by the sample sizes of the trials, gave a similar result. In the other trials, the average number of units of blood products saved was twice as large as for the trials with low risk of bias: 1.5 units (95% CI 0.9 to 2.0).</P>
<P>There was significant heterogeneity for number of patients failing initial haemostasis and for rebleeding, both for trials with low risk of bias and for other trials, with I<SUP>2</SUP> around 50% to 60%. The estimates for number of patients failing initial haemostasis were similar for trials with low risk of bias and for other trials, and the combined estimate showed a significant reduction, RR 0.68 (95% CI 0.54 to 0.87). For rebleeding, the estimates were very different, RR 0.84 (95% CI 0.52 to 1.37) for trials with low risk of bias and 0.36 (95% CI 0.19 to 0.68) for other trials. Use of balloon tamponade was rarely reported.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>It is complicated to perform trials in acute bleeding oesophageal varices. Unlike many other medical emergencies, for example, myocardial infarction, patients are scarce and therefore, it is difficult to obtain a consecutive flow of patients and a routine that is strictly adhered to. Furthermore, the threshold for giving blood transfusions and using balloon tamponade, and the possibility of having acute diagnostic and therapeutic endoscopy performed, is likely to vary considerably, even within the same trial, depending on the available clinicians and their competing duties. Heterogeneity is therefore to be expected, both within and between trials. Potential sources of heterogeneity between trials are: quality of allocation concealment; blinding of clinicians, outcome assessors and data analysts; nature and dose of drugs; duration of treatment; Child's grade; type of bleeding (index versus interval bleeding); inclusion before or after end of haemorrhage; criteria for definition of successful initial haemostasis and for rebleeding episodes; presence of ulcers or gastric varices; time between randomisation and start of treatment; confirmation of diagnosis by acute endoscopy; concomitant use of sclerotherapy or ligation; and concomitant use of balloon tamponade, transfusions and drugs.</P>
<P>Apart from mortality, there was considerable heterogeneity between the reviewed trials. The causes for heterogeneity can be explored by sensitivity analyses, for example, by analysing subgroups of trials or by relating the effect to dose or other covariates. However, there is a narrow limit to the number of exploratory analyses one can perform in a small sample of trials, and such analyses should preferably be specified in the protocol to avoid spurious conclusions, arising from data driven <I>post hoc</I> analyses. The most acceptable subgroup analyses are those for which there is empirical evidence that the grouping criterion is related to the size of the effect. We therefore limited subgroup analysis to double-blind trials with an adequately concealed randomisation since such trials are expected to give the most unbiased effect estimates (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). As expected, other trials reported more positive effects than trials with low risk of bias. This was also shown in a meta-analysis that compared emergency sclerotherapy with vasoactive drugs (<LINK REF="REF-D_x0027_Amico-2003" TYPE="REFERENCE">D'Amico 2003</LINK>) where the mortality risk difference was 1% (95% CI -4% to 7%) in good-quality trials and 8% (2% to 14%) in poor-quality trials, ie, the mortality difference was statistically significant in the poor-quality trials which is misleading. </P>
<P>Even after this division of the trials, considerable heterogeneity remained. Unfortunately, other trial characteristics have not indicated a plausible explanation why the results of the various trials are so different. Some researchers have suggested that the trial by Valenzuela is atypical because of the high rate of bleeding control in the placebo group, 83% (<LINK REF="STD-Valenzuela-1989" TYPE="STUDY">Valenzuela 1989</LINK>). However, this result may simply be a random high; it refers to only 36 patients and the 95% CI for the true rate is 67% to 94%. Sixty-seven per cent is not an unusually high rate and the measured rate of 83% is not significantly different from the 65% rate in the experimental group. Perhaps even more important, the recorded rate is a matter of definition. For how long should the gastric aspirate be without blood and what interval is necessary between bleeds before it should be called a bleeding arrest rather than just a temporary control of bleeding? Finally, Valenzuela's results are in good agreement with the other trials apart from number of patients with bleeding control (initial haemostasis) which agrees well, however, with the result of another trial (<LINK REF="STD-G_x00f8_tzsche-1995" TYPE="STUDY">Gøtzsche 1995</LINK>). </P>
<P>The applied doses and length of treatment varied between the trials. There are now many trials, which have used varying doses in pathophysiological experiments, measuring, for example, hepatic venous pressure gradient and variceal pressure. The results from such trials are conflicting. In one experiment, the authors found that the effects of bolus doses of octreotide were independent of dose and transitory, and that tachyphylaxis developed quickly (<LINK REF="REF-Escorsell-2001" TYPE="REFERENCE">Escorsell 2001</LINK>). Since it is also unclear whether results from such experiments can be translated directly to the clinical setting and to clinical outcomes, and since there was no obvious relation between dose and effect in the reviewed trials, we did not pursue this possibility further. Our review cannot give reliable evidence about the relative effects of the individual somatostatin analogues as they were all compared with placebo or no treatment, and not with each other, but with this important reservation, they seemed to have similar effects.</P>
<P>The length of treatment is probably of minor importance since, if effective, one would expect the drugs to be superior to no treatment whether the treatment was stopped two hours after bleeding arrest or was given for five days continuously. As expected, length of treatment was unrelated to the outcome. </P>
<P>Seven of the trials we identified were reported as abstracts (<LINK REF="STD-Isaac-1994" TYPE="STUDY">Isaac 1994</LINK>; <LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK>; <LINK REF="STD-Burroughs-1996" TYPE="STUDY">Burroughs 1996</LINK>; <LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK>; <LINK REF="STD-Signorelli-1996" TYPE="STUDY">Signorelli 1996</LINK>; <LINK REF="STD-Signorelli-1997" TYPE="STUDY">Signorelli 1997</LINK>; <LINK REF="STD-Souza-2003" TYPE="STUDY">Souza 2003</LINK>). We contacted the authors but received only three replies. One author sent a published paper (<LINK REF="STD-Shiha-1996" TYPE="STUDY">Shiha 1996</LINK>), another an unpublished manuscript (<LINK REF="STD-Moret_x00f3_-1994" TYPE="STUDY">Moretó 1994</LINK>), and a third noted that the trial was submitted for publication (<LINK REF="STD-Burroughs-1996" TYPE="STUDY">Burroughs 1996</LINK>). An additional trial of about 150 patients, which we had wished to include in an earlier version of this review (that also comprised trials in patients with early rebleeding), appears not to have been reported at all (<LINK REF="STD-UCB-trial-1996" TYPE="STUDY">UCB trial 1996</LINK>). When we contacted the sponsor, UCB in Belgium, we received a letter that stated that UCB is an ethical company, and that all data are proprietary solely to the UCB who has the exclusive right to make whatever it deems desirable. We find this attitude unethical as trial participants contribute altruistically to research for the benefit of future patients (<LINK REF="REF-Chalmers-1990" TYPE="REFERENCE">Chalmers 1990</LINK>). </P>
<P>Our results are likely exaggerated because of publication bias (<LINK REF="REF-Stern-1997" TYPE="REFERENCE">Stern 1997</LINK>; <LINK REF="REF-Hopewell-2004" TYPE="REFERENCE">Hopewell 2004</LINK>; <LINK REF="REF-Scherer-2004" TYPE="REFERENCE">Scherer 2004</LINK>) and reporting bias within trials (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>). In <LINK REF="STD-Shah-1996" TYPE="STUDY">Shah 1996</LINK>, for example, there were several important discrepancies between data as published in a conference abstract and data reported in a subsequent journal article (see Table: Characteristics of included studies). Patients could also have been excluded in those trial reports that lacked a satisfactory account of all randomised patients. In two trials, mortality was given as percentages of patients which did not concord with the number randomised, no matter how many patients we assumed could have been excluded from the analysis (<LINK REF="STD-Signorelli-1996" TYPE="STUDY">Signorelli 1996</LINK>; <LINK REF="STD-Freitas-2000" TYPE="STUDY">Freitas 2000</LINK>). <BR/> <BR/>The purpose of a meta-analysis is to give a general overview of treatments, rather than paying attention to specific details such as one might wish to do in an individual trial. It is therefore sensible to include all randomised trials. In narrative review articles and editorials, somatostatin, octreotide, and other treatments are frequently recommended for emergency treatment of bleeding oesophageal varices, sometimes with claims of bleeding control in up to 80% (<LINK REF="REF-Sharara-2001" TYPE="REFERENCE">Sharara 2001</LINK>) or even 90% to 95% of the cases (<LINK REF="REF-Bornman-1994" TYPE="REFERENCE">Bornman 1994</LINK>; <LINK REF="REF-Williams-1994" TYPE="REFERENCE">Williams 1994</LINK>). Such claims are misleading, as the bleeding often stops spontaneously. Placebo may apparently 'control' bleeding in an impressive number of cases, and clinicians may feel that their preferred intervention is effective, whatever its nature. Systematic reviews of rigorously performed randomised trials with a placebo or a no-treatment control group is the only reliable way of judging the effect of any remedy in bleeding oesophageal varices. </P>
<P>The most relevant outcome measures seem to be mortality and bleeding (measured as the number of blood transfusions) since other outcome measures are derived from these. It should be noted, however, that number of transfusions is a surrogate outcome that can be unreliable in trials that are not effectively blinded. In fact, we found that the number of saved transfusions in the unblinded trials was twice the number in the blinded trials. Numbers with rebleeding were also quite different for the two groups of trials, with the most optimistic estimate obtained in the unblinded trials. Criteria for blood transfusions, bleeding control, and the timing of the measurements were rarely stated in the trial reports, and if there were none in the trial protocols either, there is a substantial risk for biased assessments. We agree with the authors of a recent trial report who noted that: "For a devastating medical emergency like acute variceal bleeding, the only outcome that really matters is survival, since a better hemostasis control without a greater survival will not be translated into a better quality of life to patients who will survive from hours to a few days in the hospital" (<LINK REF="STD-Morales-2007" TYPE="STUDY">Morales 2007</LINK>).</P>
<P>The somatostatin analogues did not have a significant effect on mortality whereas they had a significant effect on number of blood transfusions. However, the total drug effect, combining the number of transfusions used during both the acute bleeding and during any rebleeds, corresponded to only one half unit of blood saved per patient in the trials with low risk of bias. It is doubtful whether this effect is worthwhile.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>The effect of somatostatin analogues corresponded to one half unit of blood saved per patient. It is doubtful whether this effect is worthwhile.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Our findings do not suggest a need for further placebo-controlled trials of the type reviewed here. A huge placebo controlled trial is needed if one wishes to rule out the possibility that a worthwhile effect on mortality may have been overlooked. Since the point estimate for relative risk was 0.97 for the trials with low risk of bias and the control group death rate was 19%, it would require 25,000 patients in each group to be 20% certain not to overlook such a difference in mortality. If one uses the most optimistic mortality estimate compatible with our data which is the lower limit of the confidence interval, it would require 1,000 patients per group not to overlook such a 25% reduction in mortality. It should be noted, however, that such a large effect on mortality is highly unlikely, given the data we have presented in this review. It is therefore difficult to justify further placebo-controlled trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-11 10:23:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We thank Michel Beauchant, Andrew Burroughs, Paul Calès, Julio Pereira Lima, Gamal Shiha, and Joseph Sung for providing additional information on their trials and Manuel Moretó for sending an unpublished manuscript.<BR/>
<BR/>Contact Editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-01-17 11:04:24 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Peter Gøtzsche was the lead investigator of one of the included trials. Somatostatin was purchased at usual market price and the pharmaceutical company delivering coded drugs did not provide financial support to the trial and was not involved in its planning, execution, analysis, or publication.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Peter Gøtzsche was the sole author of this review until the 2005 update for which update Asbjørn Hróbjartsson independently extracted data on the additional in- and excluded trials. Text prepared by Peter Gøtzsche and commented upon by Asbjørn Hróbjartsson. Peter Gøtzsche is guarantor.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-11-29 11:24:55 +0100" MODIFIED_BY="dimitrinka nikolova">
<STUDIES MODIFIED="2011-11-29 11:24:55 +0100" MODIFIED_BY="Sarah L Klingenberg">
<INCLUDED_STUDIES MODIFIED="2011-11-29 11:12:21 +0100" MODIFIED_BY="Sarah L Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Avgerinos-1997" MODIFIED="2011-11-29 11:12:21 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Avgerinos 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-11-29 11:12:21 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Avgerinos, A., Nevens, F., Raptis, S. et al. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in Acute Bleeding Oesophageal Variceal Episodes: thee European ABOVE Study [abstract]. Gut 1996; 39:A1.&lt;/p&gt;" NOTES_MODIFIED="2011-11-29 11:12:21 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group</AU>
<TI>Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in Acute Bleeding Oesophageal Variceal Episodes: the European ABOVE Study [abstract]</TI>
<SO>Gut</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>A1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Avgerinos, A., Nevens, F., Raptis, S. et al. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: The European ABOVE Study [AASLD abstract]. Hepatology 1996; 24:191A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group</AU>
<TI>Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: The European ABOVE Study [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>4 Pt 2</NO>
<PG>191A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Avgerinos, A., Nevens, F., Raptis, S. et al. Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in Acute Bleeding Oesophageal Variceal Episodes: the European ABOVE Study [UEGW abstract]. United European Gastroenterology Week, Paris 1996; OP1 0001.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group</AU>
<TI>Early administration of natural somatostatin (S) increases the efficacy of sclerotherapy (ES) in acute bleeding oesophageal variceal episodes: the European ABOVE Study [UEGW abstract]</TI>
<SO>United European Gastroenterology Week, Paris</SO>
<YR>1996</YR>
<VL>OP1</VL>
<PG>0001</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Avgerinos A, Nevens F, Raptis S, Fevery J, and the ABOVE Study Group</AU>
<TI>Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<PG>1495-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998049750"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Avgerinos A, Nevens F, Raptis S, Fevery J, for the ABOVE study group</AU>
<TI>Somatostatin for acute oesophageal variceal bleeding [reply]</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>911-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Somatostatin for acute oesophageal variceal bleeding [comment]</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>911</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Besson-1995" MODIFIED="2011-11-25 14:19:40 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Besson 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-11-25 14:19:40 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al. Sclerotherapy with or without octreotide for acute variceal bleeding. N Engl J Med 1995;333:555-60.&lt;/p&gt;" NOTES_MODIFIED="2011-11-25 14:19:40 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Besson I, Ingrand P, Person B, Boutroux D, Heresbach D, Bernard P, et al</AU>
<TI>Sclerotherapy with or without octreotide for acute variceal bleeding</TI>
<SO>New England Journal of Medicine</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>555-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995349685"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Ingrand P, Rodriguez B, Silvain C, Beauchant M, and a multicenter group. Predictive factors of early variceal bleeding control after emergency sclerotherapy: role of octreotide [abstract]. J Hepatol 1997; suppl 1(vol 26):P/C02-15.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ingrand P, Rodriguez B, Silvain C, Beauchant M, and a multicenter group</AU>
<TI>Predictive factors of early variceal bleeding control after emergency sclerotherapy: role of octreotide [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1997</YR>
<VL>26 Suppl 1</VL>
<PG>P/C02-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Silvain C, Multricentric Group. A comparison of octreotide combined with endoscopic sclerosis to endoscopic sclerosis alone in the treatment of acute variceal bleeding: a randomized double-blind placebo-controlled trial [EASL abstract]. J-Hepatol. 23. 1995:S70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silvain C, Multricentric Group</AU>
<TI>A comparison of octreotide combined with endoscopic sclerosis to endoscopic sclerosis alone in the treatment of acute variceal bleeding: a randomized double-blind placebo-controlled trial [EASL abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>1995</YR>
<VL>23 Suppl 1</VL>
<PG>S70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burroughs-1990" NAME="Burroughs 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, McCormick PA, Hughes MD, Sprengers D, D'Heygere F, McIntyre N</AU>
<TI>Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early rebleeding</TI>
<SO>Gastroenterology</SO>
<YR>1990</YR>
<VL>99</VL>
<PG>1388-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991007091"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Burroughs, A. K, McCormick, P. A, Sprengers, D., et al. Randomized, double-blind placebo controlled study of somatostatin for control of variceal bleeding [AASLD abstract]. Hepatology 1988; 8:1221.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N, et al</AU>
<TI>Randomized, double-blind placebo controlled study of somatostatin for control of variceal bleeding [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>1988</YR>
<VL>8</VL>
<PG>1221</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N. Randomised double-blind placebo controlled study of somatostatin for control of variceal bleeding [abstract]. Gut. 29. 1988:A1495.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, McCormick PA, Sprengers D, Hughes M, D'Heygere F, McIntyre N</AU>
<TI>Randomised double-blind placebo controlled study of somatostatin for control of variceal bleeding [abstract]</TI>
<SO>Gut</SO>
<YR>1988</YR>
<VL>29</VL>
<NO>10</NO>
<PG>A1495</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burroughs-1996" NAME="Burroughs 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;International Octreotide Varices Study Group an Burroughs, A. K. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures [AASLD abstract]. Hepatology 1996; 24:352A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK</AU>
<TI>International Octreotide Varices Study Group. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial/failures [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<PG>352A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cal_x00e8_s-2001" NAME="Calès 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Cales, Paul French club for the study of Pht. Early administration of vapreotide, a new somatostatin analoque, and endoscopic therapy for acute portal hypertensive bleeding in patients with cirrhosis. A randomized trial. [abstract]. Hepatology 1999; 30:419A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calès P for the French Club for the Study of Pht</AU>
<TI>Early administration of vapreotide, a new somatostatin analogue, and endoscopic therapy for acute portal hypertensive bleeding in patients with cirrhosis. A randomized trial [abstract 1035]</TI>
<SO>Hepatology</SO>
<YR>1999</YR>
<VL>30</VL>
<NO>4</NO>
<PG>419A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Cales P, Masliah C, Bernard B, Garnier P P, Silvain C, Szostak Talbodec N et al. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med 2001; 344(1):23-8.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Calès P, Masliah C, Bernard B, Garnier P-P, Silvain C, Szostak-Talbodec N, et al</AU>
<TI>Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>344</VL>
<NO>1</NO>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farooqi-2000" NAME="Farooqi 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Farooqi JI, Farooqi RJ, Haq N, Siddiq-Ur-Rehman, Mahmood S. Treatment and outcome of variceal bleeding - A comparison of two methods. Journal of the College of Physicians and Surgeons Pakistan 2000; 10:131-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farooqi JI, Farooqi RJ, Haq N, Siddiq-Ur-Rehman, Mahmood S</AU>
<TI>Treatment and outcome of variceal bleeding - a comparison of two methods</TI>
<SO>Journal of the College of Physicians and Surgeons in Pakistan</SO>
<YR>2000</YR>
<VL>10</VL>
<PG>131-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freitas-2000" NAME="Freitas 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Freitas D S, Sofia C, Pontes J M, Gregorio C, Cabral J P, Andrade P et al. Octreotide in acute bleeding esophageal varices: a prospective randomized study. Hepatogastroenterology 2000; 47(35):1310-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freitas DS, Sofia C, Pontes JM, Gregorio C, Cabral JP, Andrade P, et al</AU>
<TI>Octreotide in acute bleeding esophageal varices: a prospective randomized study</TI>
<SO>Hepatogastroenterology</SO>
<YR>2000</YR>
<VL>47</VL>
<NO>35</NO>
<PG>1310-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-G_x00f8_tzsche-1995" MODIFIED="2011-11-25 14:21:19 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Gøtzsche 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-11-25 14:21:19 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Gotzsche PC, Gjorup I, Bonnen H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995;310:1495-8.&lt;/p&gt;" NOTES_MODIFIED="2011-11-25 14:21:19 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F</AU>
<TI>Somatostatin versus placebo in bleeding oesophageal varices: randomised trial and meta-analysis</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>1495-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995307277"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Isaac-1994" NAME="Isaac 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Isaac, J. Pre-sclerotherapy treatment with somatostatin in bleeding oesophageal varices [abstract]. J-Gastroenterol-Hepatol 1994; 9:A35.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Isaac J</AU>
<TI>Pre-sclerotherapy treatment with somatostatin in bleeding oesophageal varices [abstract]</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1994</YR>
<VL>9</VL>
<NO>3</NO>
<PG>A35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morales-2007" NAME="Morales 2007" YEAR="2007">
<REFERENCE NOTES="&lt;p&gt;Morales GF, Pereira Lima JC, Hornos AP, Marques DL, Costa CS, Lima Pereira L, et al. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. Hepatogastroenterology 2007; 54(73):195-200.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morales GF, Pereira Lima JC, Hornos AP, Marques DL, Costa CS, Lima Pereira L, et al</AU>
<TI>Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial</TI>
<SO>Hepatogastroenterology</SO>
<YR>2007</YR>
<VL>54</VL>
<NO>73</NO>
<PG>195-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Moret_x00f3_-1994" NAME="Moretó 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Moreto, M., Zaballa, M., Ruiz-Rebollo, L., et al. Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices.[abstract]. Endoscopy 1994; 26:407.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moretó M, Zaballa M, Ruiz-Rebollo L, Calderón A, Ibánez S, Ojembarrena E, et al</AU>
<TI>Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices [abstract]</TI>
<SO>Endoscopy</SO>
<YR>1994</YR>
<VL>26</VL>
<PG>407</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moretó M, Zaballa M, Ruiz-Rebollo L, Calderón A, Ibánez S, Ojembarrena E, et al</AU>
<TI>Somatostatin as an adjuvant to emergency sclerotherapy of bleeding esophageal varices [abstract]</TI>
<SO>Gut</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>A178</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pauwels-1994" NAME="Pauwels 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Pauwels A, Florent C, Desaint B, Guivarch P, Van H, Levy V-G. Terlipressine et somatostatine dans le traitement des h&amp;#233;morragies par rupture de varices oesophagiennes. Gastroenterol Clin Biol 1994;18:388-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pauwels A, Florent C, Desaint B, Guivarch P, Van H, Levy V-G</AU>
<TI>Terlipressine et somatostatine dans le traitement des hémorragies par rupture de varices oesophagiennes [letter]</TI>
<SO>Gastroenterology and Clinical Biology</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>388-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995047127"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-1996" MODIFIED="2011-11-25 14:25:19 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Shah 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-11-25 14:25:19 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Shah HA, Mumtaz K, Jafri W, Abid S, Hamid S, Ahmad A, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage. J Ayub Med Coll Abbottabad 2005; 17(1):10-4.&lt;/p&gt;" NOTES_MODIFIED="2011-11-25 14:25:19 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah HA, Mumtaz K, Jafri W, Abid S, Hamid S, Ahmad A, et al</AU>
<TI>Sclerotherapy plus octreotide versus sclerotherapy alone in the management of gastro-oesophageal variceal hemorrhage</TI>
<SO>Journal of Ayub Medical College, Abbottabad</SO>
<YR>2005</YR>
<VL>17</VL>
<NO>1</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Shah SHA, Jafri SMW, Ahmed A, Hamid SS, Khan AH. Octreotide use in acute variceal haemorrhage: a prospective randomized study [UEGW abstract]. United European Gastroenterology Week 1996; P50 1215.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah SHA, Jafri SMW, Ahmed A, Hamid SS, Khan AH</AU>
<TI>Octreotide use in acute variceal haemorrhage: a prospective randomized study [United European Gastroenterology Week abstract 1215]</TI>
<SO>Endoscopy</SO>
<YR>1996</YR>
<VL>28</VL>
<PG>S51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Shiha-1996" NAME="Shiha 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiha G, Hamid M, El-Said SS, Farag FM, Azzam F, Askalany H</AU>
<TI>Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial</TI>
<SO>Mansoura Medical Journal</SO>
<YR>1996</YR>
<VL>26</VL>
<PG>109-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Shiha G, Sayed S, Hamid M, Farag M, Azzam F, Assalany H. Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial [abstract]. 5th United European Gastroenterology Week, Paris 2-6 Nov. 1996. Excerpta Medica 1996:OT51 1066.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shiha G, Sayed S, Hamid M, Farag M, Azzam F, Assalany H</AU>
<TI>Octreotide infusion plus emergency sclerotherapy versus sclerotherapy alone for the control of bleeding oesophageal varices: a prospective randomized clinical trial [UEGW abstract]</TI>
<SO>Excerpta Medica. 5th United European Gastroenterology Week, Paris 2-6 Nov</SO>
<YR>1996</YR>
<PG>OT51-1066</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Signorelli-1996" NAME="Signorelli 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Signorelli S, Negrini F, Paris B, Bonelli M, Girola M. Sclerotherapy with or without somatostatin or octreotide in the treatment of acute variceal haemorrhage: our experience [abstract]. Gastroenterology 1996; 110:A1326.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Signorelli S, Negrini F, Paris B, Bonelli M, Girola M</AU>
<TI>Sclerotherapy with or without somatostatin or octreotide in the treatment of acute variceal haemorrhage: our experience [abstract]</TI>
<SO>Gastroenterology</SO>
<YR>1996</YR>
<VL>110</VL>
<PG>A1326</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Signorelli-1997" NAME="Signorelli 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Signorelli, S., Paris, B., Negrini, F. et al. Esophageal varices bleeding: comparison between treatment with sclerotherapy alone vs sclerotherapy plus octreotide [abstract]. Hepatology 1997; 26:137A.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Signorelli S, Paris B, Negrini F, Bonelli M, Auriemma L</AU>
<TI>Esophageal varices bleeding: comparison between treatment with sclerotherapy alone vs sclerotherapy plus octreotide [abstract]</TI>
<SO>Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>4 Pt 2</NO>
<PG>137A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souza-2003" NAME="Souza 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Souza, F. C, Arantes, V., Cambraia, R. D, et al. Randomized, double blind, trial of octreotide plus endoscopic treatment in controlling gastroesophageal variceal bleeding.[abstract]. J Hepatol 2003; 38:70.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souza FC, Arantes V, Cambraia RD, Cangussu LOF, Couto OFM, Teixeira R</AU>
<TI>Randomized, double blind, trial of octreotide plus endoscopic treatment in controlling gastroesophageal variceal bleeding [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<PG>70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sung-1995" NAME="Sung 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sung JJY, Chung SCS, Yung MY, Lai CW, Lau JYW, Lee YT, et al</AU>
<TI>Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>346</VL>
<PG>1666-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996110602"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Valenzuela-1989" NAME="Valenzuela 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Valenzuela JE, Schubert T, Fogel MR, Strong RM, Levine J, Mills PR, et al. A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices. Hepatology 1989;10:958-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Valenzuela JE, Schubert T, Fogel MR, Strong RM, Levine J, Mills PR, et al</AU>
<TI>A multicenter, randomized, double-blind trial of somatostatin in the management of acute hemorrhage from esophageal varices</TI>
<SO>Hepatology</SO>
<YR>1989</YR>
<VL>10</VL>
<NO>6</NO>
<PG>958-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990061178"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Villanueva-2001" NAME="Villanueva 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Villanueva C, Ortiz J, Minana J, Soriano G, Sabat M, Boadas J, et al</AU>
<TI>Somatostatin treatment and risk stratification by continuous portal pressure monitoring during acute variceal bleeding</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>121</VL>
<PG>110-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuberi-2000" NAME="Zuberi 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Zuberi BF, . = Baloch Q. Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis. Am J Gastroenterol 2000; 95:768-71.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zuberi BF, Baloch Q</AU>
<TI>Comparison of endoscopic variceal sclerotherapy alone and in combination with octreotide in controlling acute variceal hemorrhage and early rebleeding in patients with low-risk cirrhosis</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2000</YR>
<VL>95</VL>
<NO>3</NO>
<PG>768-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Zuberi BF, Balouch Q. Endoscopic variceal sclerotherapy and octreotide in management of variceal haemorrhage and early. J of Gastroenterol and Hepatol 1999; 14:A15.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuberi BF, Balouch Q</AU>
<TI>Endoscopic variceal sclerotherapy and octreotide in management of variceal haemorrhage and early re-bleeding [abstract]</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>1999</YR>
<VL>14</VL>
<PG>A15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2011-11-29 11:24:55 +0100" MODIFIED_BY="Sarah L Klingenberg">
<STUDY DATA_SOURCE="PUB" ID="STD-Brunati-1996" MODIFIED="2011-11-29 11:24:55 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Brunati 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brunati S, Ceriani R, Curioni R, Brunelli L, Repaci G, Morini L</AU>
<TI>Sclerotherapy alone vs. sclerotherapy plus terlipressin vs. sclerotherapy plus octreotide in the treatment of acute variceal haemorrhage [abstract]</TI>
<SO>Hepatology</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>4 Pt 2</NO>
<PG>207A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-11-29 11:24:55 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Ceriani R, Curioni R, Morini L, Repaci G, Brunati S. Sclerotherapy alone (ES) vs. sclerotherapy plus terlipressin (EST) vs. sclerotherapy plus octrotide (ESO) in the treatment of acute variceal bleeding (abstract). Gastraenterol 1997; 112:A1238.&lt;/p&gt;" NOTES_MODIFIED="2011-11-29 11:24:55 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ceriani R, Curioni R, Morini L, Repaci G, Brunati S</AU>
<TI>Sclerotherapy alone (ES) vs. sclerotherapy plus terlipressin (EST) vs. sclerotherapy plus octreotide (ESO) in the treatment of acute variceal bleeding [abstract]</TI>
<SO>Gastroenterology</SO>
<YR>1997</YR>
<VL>112</VL>
<PG>A1238</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-D_x0027_Amico-1998" NAME="D'Amico 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;D'Amico-G, Politi-F, Morabito-A, D'Antoni-A, Guerrera-D, Giannuoli-G et al. Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial. Hepatology 1998; 28:1206-14.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G, Politi F, Morabito A, D'Antoni A, Guerrera D, Giannuoli G, et al</AU>
<TI>Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>1206-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jenkins-1997" MODIFIED="2011-11-25 14:29:03 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Jenkins 1997" YEAR="">
<REFERENCE MODIFIED="2011-11-25 14:29:03 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S et al. Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ 1997;315:1338-41.&lt;/p&gt;" NOTES_MODIFIED="2011-11-25 14:29:03 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jenkins SA, Baxter JN, Critchley M, Kingsnorth AN, Makin CA, Ellenbogen S, et al</AU>
<TI>Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>1338-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1998066478"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Primignani-1995" NAME="Primignani 1995" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, et al. Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 1995;21:1322-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Primignani M, Andreoni B, Carpinelli L, Capria A, Rocchi G, Lorenzini I, et al</AU>
<TI>Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>21</VL>
<NO>5</NO>
<PG>1322-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995255802"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruiz-del-Arbol-1994" NAME="Ruiz del Arbol 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Ruiz del Arbol, L., Monescillo, A., Arocena, C. et al. The pharmacological therapy during the treatment of acute variceal bleeding (A.V.B.) evaluated by variceal pressure measurement [IASL abstract]. Hepatology 1994; 19:119I.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz del Arbol L, Monescillo A, Arocena C, Defarges V, Gisbert J, Vicente M, et al</AU>
<TI>The pharmacological therapy during the treatment of acute variceal bleeding (A.V.B.) evaluated by variceal pressure measurement [IASL abstract]</TI>
<SO>Hepatology</SO>
<YR>1994</YR>
<VL>19</VL>
<NO>4</NO>
<PG>119I</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shields-1993" NAME="Shields 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Shields R, Jenkins SA, Baxter JN, Sutton R, Ellenbogen S. Octreotide in the long term management of portal hypertension: preliminary results of a prospective randomised controlled clinical trial [abstract]. Gastroenterol 1993;4:A991.&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Shields R, Jenkins SA, Baxter JN, Sutton R, Ellenbogen S</AU>
<TI>Octreotide in the long term management of portal hypertension: preliminary results of a prospective randomised controlled clinical trial [abstract]</TI>
<SO>Gastroenterology Supplements</SO>
<YR>1993</YR>
<VL>4</VL>
<PG>A991</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silva-2004" MODIFIED="2011-11-25 14:29:49 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Silva 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-11-25 14:29:49 +0100" MODIFIED_BY="Sarah L Klingenberg" NOTES="&lt;p&gt;Silva G, Quera R, Fluxa F, Sanhueza E, Segovia R, Brahm J, et al. [Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study]. Rev Med Chil 2004; 132(3):285-94.&lt;/p&gt;" NOTES_MODIFIED="2011-11-25 14:29:49 +0100" NOTES_MODIFIED_BY="Sarah L Klingenberg" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silva G, Quera R, Fluxa F, Sanhueza E, Segovia R, Brahm J, et al</AU>
<TI>[Octreotide administration and/or endoscopic treatment in cirrhotic patients with acute variceal bleeding: a multicentric study]</TI>
<SO>Revista Medica de Chile</SO>
<YR>2004</YR>
<VL>132</VL>
<NO>3</NO>
<PG>285-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-UCB-trial-1996" NAME="UCB trial 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<TI>Somatostatin in the control of early rebleeding after sclerotherapy for acute bleeding varices: a multicentre, double-blind randomised placebo-controlled study</TI>
<SO>Trial MPCE93M0601/1V, sponsored by UCB, Belgium. Unpublished</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-11-29 11:19:20 +0100" MODIFIED_BY="dimitrinka nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2011-11-25 14:32:52 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-Albillos-1994" MODIFIED="2011-11-25 14:12:19 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Albillos 1994" TYPE="JOURNAL_ARTICLE">
<AU>Albillos A, Rossi I, Iborra J, Lledo JL, Calleja JL, Barrios C, et al</AU>
<TI>Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension</TI>
<SO>Journal of Hepatology</SO>
<YR>1994</YR>
<VL>21</VL>
<NO>1</NO>
<PG>88-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995052506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baveno-II-1996" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Baveno II 1996" TYPE="BOOK">
<AU>De Franchis R, editor</AU>
<SO>Portal hypertension II. Proceedings of the second Baveno international consensus workshop on definitions, methodology and therapeutic strategies</SO>
<YR>1996</YR>
<PB>Blackwell Science Ltd</PB>
<CY>Oxford, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bornman-1994" MODIFIED="2011-11-25 14:12:27 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Bornman 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bornman PC, Krige JEJ, Terblanche J</AU>
<TI>Management of oesophageal varices</TI>
<SO>Lancet</SO>
<YR>1994</YR>
<VL>343</VL>
<NO>8905</NO>
<PG>1079-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994211066"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1990" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Chalmers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I</AU>
<TI>Underreporting research is scientific misconduct</TI>
<SO>JAMA</SO>
<YR>1990</YR>
<VL>263</VL>
<PG>1405-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<PG>2457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cirera-1995" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Cirera 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cirera I, Feu F, Luca A, Garcia-Pagan JC, Fernandez M, Escorsell A, et al</AU>
<TI>Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation</TI>
<SO>Hepatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>1</NO>
<PG>106 -11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995324860"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2003" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="D'Amico 2003" TYPE="JOURNAL_ARTICLE">
<AU>D'Amico G, Pietrosi G, Tarantino I, Pagliaro L</AU>
<TI>Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis</TI>
<SO>Gastroenterology</SO>
<YR>2003</YR>
<VL>124</VL>
<PG>1277-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Escorsell-2001" MODIFIED="2011-11-25 14:12:40 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Escorsell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Escorsell A, Bandi JC, Andreu V, Moitinho E, Garcia-Pagan JC, Bosch J, et al</AU>
<TI>Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension</TI>
<SO>Gastroenterology</SO>
<YR>2001</YR>
<VL>120</VL>
<PG>161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greco-1982" MODIFIED="2011-11-25 14:13:32 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Greco 1982" TYPE="JOURNAL_ARTICLE">
<AU>Greco AV, Bianco A, Altomonte L, D'Acquarica L, Ghirlanda G</AU>
<TI>Effect of somatostatin on lower esophageal sphincter (LES) pressure and serum gastrin in normal and achalasic subjects</TI>
<SO>Hormone and Metabolic Research</SO>
<YR>1982</YR>
<VL>14</VL>
<PG>26-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1982140481"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1989" MODIFIED="2011-11-25 14:13:36 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gøtzsche 1989" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1989</YR>
<VL>36</VL>
<PG>493-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1990031801"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hanisch-1992" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Hanisch 1992" TYPE="JOURNAL_ARTICLE">
<AU>Hanisch E, Doertenbach J, Usadel KH</AU>
<TI>Somatostatin in acute bleeding oesophageal varices: pharmacology and rationale for use</TI>
<SO>Drugs</SO>
<YR>1992</YR>
<VL>44</VL>
<NO>Suppl 2</NO>
<PG>24-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993048855"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2011-11-25 14:31:36 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopewell-2004" MODIFIED="2011-11-25 14:31:47 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Hopewell 2004" TYPE="COCHRANE_REVIEW">
<AU>Hopewell S, Clarke M, Stewart L, Tierney J</AU>
<TI>Time to publication for results of clinical trials (Cochrane Methodology Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-05 14:15:30 +0200" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-05-05 14:15:30 +0200" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.MR000011.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kleber-1988" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Kleber 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kleber G, Sauerbruch T, Fisher G, Paumgartner G</AU>
<TI>Somatostatin does not reduce oesophageal variceal pressure in liver cirrhotics</TI>
<SO>Gut</SO>
<YR>1988</YR>
<VL>29</VL>
<PG>153-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1988152560"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lamberts-1996" MODIFIED="2011-11-25 14:13:21 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Lamberts 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ</AU>
<TI>Octreotide</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>246-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996132562"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCormick-1992" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="McCormick 1992" TYPE="JOURNAL_ARTICLE">
<AU>McCormick PA, Biagini MR, Dick R, Greenslade L, Chin J, Cardin F, et al</AU>
<TI>Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study</TI>
<SO>Hepatology</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>5</NO>
<PG>1180-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1993052079"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-M_x00f8_ller-1997" MODIFIED="2011-11-25 14:13:40 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Møller 1997" TYPE="JOURNAL_ARTICLE">
<AU>Møller S, Brinch K, Henriksen JH, Becker U</AU>
<TI>Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis</TI>
<SO>Journal of Hepatology</SO>
<YR>1997</YR>
<VL>26</VL>
<NO>5</NO>
<PG>1026-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nevens-1994" MODIFIED="2011-11-25 14:13:43 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Nevens 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nevens F, Sprengers D, Fevery J</AU>
<TI>The effect of different doses of a bolus injection of somatostatin combined with a slow infusion on transmural oesophageal variceal pressure in patients with cirrhosis</TI>
<SO>Journal of Hepatology</SO>
<YR>1994</YR>
<VL>20</VL>
<NO>1</NO>
<PG>27-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994260076"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Samnegaard-1980" MODIFIED="2011-11-25 14:13:47 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Samnegaard 1980" TYPE="JOURNAL_ARTICLE">
<AU>Samnegaard H, Tyden G, Thulin L, Friman L, Uden R</AU>
<TI>Effect of somatostatin on regional splanchnic blood flows in man: angiographic studies</TI>
<SO>Acta Chirurgica Scandinavica. Supplementum</SO>
<YR>1980</YR>
<VL>500</VL>
<PG>71-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scherer-2004" MODIFIED="2011-11-25 14:32:25 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Scherer 2004" TYPE="COCHRANE_REVIEW">
<AU>Scherer RW, Langenberg P</AU>
<TI>Full publication of results initially presented in abstracts (Cochrane Methodology Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-05-05 14:18:48 +0200" MODIFIED_BY="dimitrinka nikolova">
<IDENTIFIER MODIFIED="2008-05-05 14:18:48 +0200" MODIFIED_BY="dimitrinka nikolova" TYPE="DOI" VALUE="10.1002/14651858.MR000005.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995123716"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sharara-2001" MODIFIED="2008-05-20 16:13:38 +0200" MODIFIED_BY="dimitrinka nikolova" NAME="Sharara 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sharara AI, Rockey DC</AU>
<TI>Gastroesophageal variceal hemorrhage</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<PG>669-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stern-1997" MODIFIED="2011-11-25 14:32:41 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Stern 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stern JM, Simes RJ</AU>
<TI>Publication bias: evidence of delayed publication in a cohort study of clinical research projects</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>640-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1994" MODIFIED="2011-11-25 14:32:52 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Williams 1994" TYPE="JOURNAL_ARTICLE">
<AU>Williams SGJ, Westaby D</AU>
<TI>Management of variceal haemorrhage</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1994</YR>
<VL>308</VL>
<PG>1213-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994236061"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2011-11-29 11:19:20 +0100" MODIFIED_BY="dimitrinka nikolova">
<REFERENCE ID="REF-G_x00f8_tzsche-1995" MODIFIED="2011-11-25 14:18:36 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Gøtzsche 1995" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F</AU>
<TI>Somatostatin versus placebo in bleeding oesophageal varices: randomised trial and meta-analysis</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>1995</YR>
<VL>310</VL>
<PG>1495-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995307277"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1997" MODIFIED="2011-11-29 11:19:20 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Gøtzsche 1997" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC</AU>
<TI>Somatostatin or octreotide versus placebo in bleeding oesophageal varices</TI>
<SO>The Cochrane Library</SO>
<YR>1997</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1998" NAME="Gøtzsche 1998" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC</AU>
<TI>Somatostatin or octreotide versus placebo in bleeding oesophageal varices</TI>
<SO>The Cochrane Library</SO>
<YR>1998</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2002" NAME="Gøtzsche 2002" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC</AU>
<TI>Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review)</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2005" MODIFIED="2011-11-25 14:27:33 +0100" MODIFIED_BY="dimitrinka nikolova" NAME="Gøtzsche 2005" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Hrobjartsson A</AU>
<TI>Somatostatin analogues for acute bleeding oesophageal varices</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-11-25 14:27:30 +0100" MODIFIED_BY="Sarah L Klingenberg">
<IDENTIFIER MODIFIED="2011-11-25 14:27:30 +0100" MODIFIED_BY="Sarah L Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD000193.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-01-11 10:26:17 +0100" MODIFIED_BY="Sarah L Klingenberg">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-01-11 10:26:17 +0100" MODIFIED_BY="Sarah L Klingenberg" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Avgerinos-1997">
<CHAR_METHODS>
<P>Generation of allocation sequence: computer, blocks of four; concealment of allocation sequence: sealed, opaque envelopes.</P>
<P>Blinding: double-blind, analysis also blinded.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: five.</P>
<P>Follow-up period: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Greece, Belgium, The Netherlands. N = 205 (no exclusions from analyses).<BR/>Clinical suspicion of upper-gastrointestinal bleeding (endoscopy after randomisation, performed in 201/205 patients, varices found in 152).<BR/>Cirrhosis (mostly alcoholic) or history and examination compatible with portal hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin infusion 250 µg/h for 5 days plus up to eight bolus injections of 250 µg.</P>
<P>Control: placebo.</P>
<P>All patients with varices underwent sclerotherapy (77 versus 75).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 6 weeks.<BR/>Number of blood products.<BR/>Failure of therapy.<BR/>Ease of sclerotherapy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>49/205 had other source of bleeding than varices. SDs in the paper are not SDs but SEs.<BR/>Funding: industry (UCB).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 10:24:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Besson-1995">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS, blocks of four; concealment of allocation sequence: prepackaged and numbered by company, code kept by statistician.</P>
<P>Blinding: double-blind.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: no information.</P>
<P>Follow-up period: 15 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>France. N = 199 (no exclusions from analysis, no patients lost to follow-up).<BR/>Endoscopically confirmed acute or recently (&lt; 24 h) bleeding varices.<BR/>Liver cirrhosis (mostly alcoholic).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 25 µg/hour for 5 days.</P>
<P>Control: placebo.</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 15 days.<BR/>Survival without rebleeding.<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (24 h).<BR/>Number with rebleeding (1 to 5 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-11 10:24:25 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Placebo patients had a worse prognosis than octreotide treated patients, eg, 47 per cent versus 26 per cent were in Child-Pugh class C.<BR/>Funding: industry (Sandoz provided the drugs).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Burroughs-1990">
<CHAR_METHODS>
<P>Generation of allocation sequence: table of random numbers; concealment of allocation sequence: sealed opaque envelopes.</P>
<P>Blinding: double-blind, analysis also blinded.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: none.</P>
<P>Follow-up period: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>UK. N = 133 bleeding episodes (13 excluded after randomisation as endoscopy showed non-variceal bleeding). <BR/>Clinical suspicion of bleeding varices (endoscopy before randomisation in 62/120 of the bleeding episodes).<BR/>Half of the patients had alcoholic cirrhosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin infusion 250 µg bolus and 250 µg/h for 5 days.</P>
<P>Control: placebo.</P>
<P>Trial failures (22 versus 35) underwent sclerotherapy or staple transection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 30 days.<BR/>Number of blood and plasma transfusions.<BR/>Number with initial haemostasis (5 days).<BR/>Number with balloon tamponade.<BR/>Number with rebleeding (following start of infusion).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only 92 patients participated in the trial but 28 were admitted twice. Transfusions given as medians.<BR/>Funding: industry (Serono, provided drugs and contributed to the running of the trial).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Burroughs-1996">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS.</P>
<P>Blinding: double-blind. Intention-to-treat: NS.</P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: 42 and 90 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Europe and USA. N=383 (260 evaluable portal hypertensive sources, 193 variceal bleeds; exclusions from analyses not clear).<BR/>Clinical suspicion of bleeding varices (endoscopy after start of drug treatment).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 50 µg/h for 5 days.</P>
<P>Control: placebo.</P>
<P>Trial failures underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 42 and 90 days.<BR/>Number with initial haemostasis (5 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract, paper re-submitted. <BR/>Funding: industry (Sandoz).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Cal_x00e8_s-2001">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS, blocks of four; concealment of allocation sequence: prepackaged, sealed and numbered boxes by company. </P>
<P>Blinding: double-blind, analysis also blinded.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: NS. </P>
<P>Follow-up period: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>France and Switzerland. N = 227 (31 excluded from analysis as they did not bleed from portal hypertension; 7 versus 4 were lost to follow-up). <BR/>Clinical suspicion of active or recent variceal bleeding (endoscopy after randomisation).<BR/>Liver cirrhosis (mostly alcoholic).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: vapreotide infusion 50 µg bolus and 50 µg/h for 5 days.</P>
<P>Control: placebo.</P>
<P>All patients but 12 underwent sclerotherapy or band ligation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 6 weeks.<BR/>Number of blood and plasma transfusions.<BR/>Number with initial haemostasis (at endoscopy and after six and 48 hours).<BR/>Number with rebleeding (two to five days and six to 42 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No data on early (two to five days) or late (six to 42 days) recurrence of bleeding (rates were low, not significantly different).<BR/>Funding: industry (Debiopharm).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Farooqi-2000">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS. </P>
<P>Blinding: none.</P>
<P>Intention-to-treat: NS.</P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: NS.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pakistan. N = 141 (in analyses, number of randomised patients and exclusions not stated). <BR/>Endoscopically confirmed acute variceal bleeding.<BR/>Liver cirrhosis, mainly hepatitis B and C.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 50 µg/hour for 48 hours.</P>
<P>Control: no drug. </P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality.<BR/>Number with initial haemostasis.<BR/>Prevention of rebleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Substantial risk of bias: criteria for bleeding control not defined, open study, and length of follow-up not defined. <BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Freitas-2000">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS. </P>
<P>Blinding: none.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: NS. Follow-up period: 48 hours.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Portugal. N = 86 (no exclusions described, but some patients seem to be lost to follow-up, see Note field).<BR/>Active bleeding at endoscopy from varices.<BR/>Liver cirrhosis (mostly alcoholic).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 25 µg/h for 48 hours.</P>
<P>Control: no drug. </P>
<P>All patients underwent sclerotherapy or band ligation after 48 hours.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality (time period not clear, but given after 30 days in results).<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (immediately, 48 h and seven days after bleeding arrest).<BR/>Number with rebleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Mortality given as percentages of patients which do not concord with the number randomised. The mortality data (27% vs 31%) are therefore unreliable and have not been used in our meta-analyses. No reply to our letter.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-29 11:23:50 +0100" MODIFIED_BY="Sarah L Klingenberg" STUDY_ID="STD-G_x00f8_tzsche-1995">
<CHAR_METHODS>
<P>Generation of allocation sequence: table of random numbers; concealment of allocation sequence: consecutively numbered sealed medicine packages. </P>
<P>Blinding: double-blind with blinding also during data analysis and writing of manuscript.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: none.</P>
<P>Follow-up period: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Denmark. N = 86 (86 in analyses).<BR/>Clinical suspicion of bleeding varices (endoscopy ultimately performed in 81/86 of the patients).<BR/>Verified or suspected cirrhosis (mostly alcoholic).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin infusion 250 µg/h for 24 hours for each bleeding episode.</P>
<P>Control: placebo.</P>
<P>Most patients (33 versus 35) underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after six weeks.<BR/>Number of blood transfusions.<BR/>Number with balloon tamponade.<BR/>Number with initial haemostasis (24 h).<BR/>Number of bleeding episodes.<BR/>Number of days with bleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 11:23:50 +0100" MODIFIED_BY="Sarah L Klingenberg">
<P>Transfusions given as medians.<BR/>Funding: none (DuraScan delivered coded drugs, somatostatin was purchased at market price).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Isaac-1994">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS. </P>
<P>Blinding: none.</P>
<P>Intention-to-treat: NS. </P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: NS.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Singapore. N not stated (exclusions not stated).<BR/>Variceal haemorrhage.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin bolus infusion 250 µg and 250 µg/h for 15 h.</P>
<P>Control: none.</P>
<P>Drug given before sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Number of blood transfusions.<BR/>Number with initial haemostasis (15 h).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract, no reply from author to our letter.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Morales-2007">
<CHAR_METHODS>
<P>Generation of allocation sequence: computer, 4 to3 ratio; concealment of allocation sequence: "randomly assigned", "sealed opaque envelopes". </P>
<P>Blinding: placebo infusion (hospital pharmacy made the placebo infusion and covered both drugs with black protections.</P>
<P>Intention-to-treat: yes, but two patients randomised to placebo with liver carcinoma secondarily excluded. </P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: 7 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Brazil. N = 70 (68 in analyses).<BR/>Variceal bleeding, acute or recent, at endoscopy.<BR/>Cirrhosis diagnosed by liver biopsy or by clinical, biochemical and echocardiographic findings. Mostly caused by hepatitis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide bolus infusion 50 µg, 50 µg/h for 24h, and 25 µg/h for another 24h.</P>
<P>Control: placebo.</P>
<P>Drug given after sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after one week.<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (2 days).<BR/>Number with rebleeding.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Funding: Ministry of Education.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Moret_x00f3_-1994">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: opaque envelopes. </P>
<P>Blinding: double-blind.</P>
<P>Intention-to-treat: yes. </P>
<P>Interim analysis: trial stopped after pilot phase.</P>
<P>Follow-up period: till discharge from hospital.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Spain. N = 63 (63 in analyses).<BR/>Bleeding varices confirmed at endoscopy.<BR/>All but one had cirrhosis (mostly alcoholic).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin bolus infusion 250 µg.</P>
<P>Control: placebo.</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality in hospital. <BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (24 h).<BR/>Number with rebleeding (24 h).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract; unpublished manuscript provided by author. Trial addressed ease of sclerotherapy, somatostatin had an effect on this.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pauwels-1994">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS.</P>
<P>Blinding: none.</P>
<P>Intention-to-treat: no.</P>
<P>Interim analysis: no information.</P>
<P>Follow-up period: one month.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>France. N = 60 bleeding episodes (11 excluded as varices was not the source of bleeding, no information on losses to follow-up), 3 groups.<BR/>Acutely bleeding varices (diagnosis by endoscopy or lavage).<BR/>Probably cirrhosis, no details.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: somatostatin infusion 250 µg bolus and 250 µg/h till two hours after bleeding arrest. </P>
<P>Experimental 2: terlipressin.</P>
<P>Control: no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after one month.<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (48 h).<BR/>Number with balloon tamponade.<BR/>Number with rebleeding (2 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No information is given on the number of patients who underwent endoscopy.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Shah-1996">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: "sealed envelopes".</P>
<P>Blinding: unclear, see Interventions. </P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: NS. Follow-up period: NS.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pakistan. N = 105 (87 in some analyses in conference abstract, not stated whether there were exclusions or losses to follow-up). <BR/>Active variceal bleeding or recent bleed.<BR/>Type of cirrhosis mostly viral, diagnosed by biopsy or otherwise.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 50 µg/h for 36 h (conference abstract) or 48 h (article).</P>
<P>Control: no treatment according to conference abstract but placebo saline according to article.</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality.<BR/>Number with initial haemostasis (24 h).<BR/>Number with rebleeding (after 24 h).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unreliable study; contrasting information in conference abstract and full article. For example, claimed difference in mortality in abstract is not mortality, but survival without rebleeding; denominators and treatment in control group are also inconsistent. No reply to our emails.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-11-29 11:24:00 +0100" MODIFIED_BY="Sarah L Klingenberg" STUDY_ID="STD-Shiha-1996">
<CHAR_METHODS>
<P>Generation of allocation sequence: random tables; concealment of allocation sequence: sealed opaque envelopes.</P>
<P>Blinding: none.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: no information.</P>
<P>Follow-up period: 7 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Egypt. N = 189 (not stated whether there were exclusions or losses to follow-up).<BR/>Active variceal bleeding (diagnosis by endoscopy).<BR/>Probably cirrhosis, no information; half of the patients were positive for hepatitis markers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 25 µg/hour for 5 days.</P>
<P>Control: no treatment.</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 7 days.<BR/>Number of blood transfusions.<BR/>Number with rebleeding (after 7 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-29 11:24:00 +0100" MODIFIED_BY="Sarah L Klingenberg">
<P>Funding: University research project, not supported by manufacturer.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Signorelli-1996">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS.</P>
<P>Blinding: NS, probably open.</P>
<P>Intention-to-treat: NS.</P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: 5 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Italy. N = 94 (number in analyses not stated, not stated whether there were exclusions or losses to follow-up).<BR/>Acute variceal bleeding.<BR/>Type of cirrhosis not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental 1: somatostatin infusion 3.5 µg/kg/h for 5 days. </P>
<P>Experimental 2: octreotide 0.1 mg s.c. every 8 h for 5 days. </P>
<P>Control: placebo, no details whether similar to one of the drugs. </P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 5 days.<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (5 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract. Results given as percentages of patients which do not concord with the number randomised, no matter how many patients might be missing in the analyses. The data are therefore unreliable and have not been used in our meta-analyses. No reply to our letters.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Signorelli-1997">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS.</P>
<P>Blinding: none.</P>
<P>Intention-to-treat: NS.</P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: 5 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Italy. N = 86 (86 in analyses, not stated whether there were exclusions or losses to follow-up).<BR/>Acute variceal bleeding.<BR/>Type of cirrhosis not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide bolus 50 µg and infusion 25 µg/h for 5 days.</P>
<P>Control: no treatment.</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 5 days.<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (5 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract. No reply to our letters.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Souza-2003">
<CHAR_METHODS>
<P>Generation of allocation sequence: NS; concealment of allocation sequence: NS.</P>
<P>Blinding: NS.</P>
<P>Intention-to-treat: NS.</P>
<P>Interim analysis: NS. </P>
<P>Follow-up period: 3 days for bleeding, not stated for mortality.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Brazil. N = 143 (112 in analyses).<BR/>Acute variceal bleeding.<BR/>Liver cirrhosis and schistosomiasis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin infusion 100 µg bolus and 50 µg/h for 3 days.</P>
<P>Control: placebo.</P>
<P>Drugs started 2 hours before endoscopy, all were to undergo sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality.<BR/>Number with rebleeding (3 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract from 2003.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 10:26:17 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Sung-1995">
<CHAR_METHODS>
<P>Generation of allocation sequence: computer, random numbers; concealment of allocation sequence: opaque envelopes.</P>
<P>Blinding: none.</P>
<P>Intention-to-treat: no.</P>
<P>Interim analysis: NS.</P>
<P>Follow-up period: 30 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Hong Kong. N = 100 (6 excluded and 4 lost to follow-up).<BR/>Endoscopically confirmed acute or recently bleeding varices.<BR/>Most had hepatitis as cause of portal hypertension.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide bolus 50 µg and infusion 50 µg/h for 5 days.</P>
<P>Control: no treatment.</P>
<P>All patients underwent endoscopic ligation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality after 30 days.<BR/>Number of blood transfusions.<BR/>Number with initial haemostasis (24 h).<BR/>Number with balloon tamponade.<BR/>Number with rebleeding (within 2 days of variceal ligation).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-01-11 10:26:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Transfusions given as medians, SD estimated from an exact P value.<BR/>Funding: industry (Sandoz).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Valenzuela-1989">
<CHAR_METHODS>
<P>Generation of allocation sequence: computer; concealment of allocation sequence: NS.</P>
<P>Blinding: double-blind.</P>
<P>Intention-to-treat: no.</P>
<P>Interim analysis: NS. Follow-up period: not defined.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>USA. N=102 (84 in analyses).<BR/>Endoscopically confirmed acute or recently bleeding varices.<BR/>Most had alcoholic liver disease.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin infusion 250 µg bolus and 250 µg/h for up to 30 hours.</P>
<P>Control: placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality (time interval not stated).<BR/>Total volume of blood transfusions.<BR/>Number with initial haemostasis (30 h).<BR/>Time to cessation of bleeding.<BR/>Number with rebleeding (1 to 2 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Transfusions given in litres, converted to units of blood (one unit is 300 ml). <BR/>Funding: industry (Serono).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Villanueva-2001">
<CHAR_METHODS>
<P>Generation of allocation sequence: computer; concealment of allocation sequence: sealed opaque envelopes.</P>
<P>Blinding: double-blind.</P>
<P>Intention-to-treat: no.</P>
<P>Interim analysis: no. </P>
<P>Follow-up period: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Spain. N = 46 (40 in analyses, 3 very likely excluded before randomisation, not clear whether the other 3 were excluded after randomisation). <BR/>Endoscopically confirmed acute or recently bleeding varices.<BR/>Type of cirrhosis not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: somatostatin infusion 250 µg bolus every 12 h and 250 µg/h, both for 5 days. </P>
<P>Control: placebo (saline).</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mortality (4 died, not divided on treatment groups).<BR/>Total volume of blood transfusions (units of packed red cells).<BR/>Number with initial haemostasis (control of bleeding for first 24 h, and no rebleeding within next 4 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Experimental study, main outcome was hepatic venous pressure gradient.<BR/>Funding: public (hospital foundation).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-01-11 10:24:04 +0100" MODIFIED_BY="Dimitrinka Nikolova" STUDY_ID="STD-Zuberi-2000">
<CHAR_METHODS>
<P>Generation of allocation sequence: table of random numbers; concealment of allocation sequence: prepackaged, sealed and numbered cartons.</P>
<P>Blinding: double-blind.</P>
<P>Intention-to-treat: yes.</P>
<P>Interim analysis: NS. </P>
<P>Follow-up period: 5 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Pakistan. N = 70 (not stated whether there were exclusions or losses to follow-up).<BR/>First episode of active or recent variceal bleeding, endoscopically confirmed.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Experimental: octreotide infusion 50 µg/h for five days.</P>
<P>Control: placebo.</P>
<P>All patients underwent sclerotherapy.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-11 10:24:04 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Mortality after 5 days.<BR/>Number of blood and plasma transfusions during hospitalisation.<BR/>Number with initial haemostasis (24 h).<BR/>Number with rebleeding (5 days).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Twenty-two patients died before endoscopy and were therefore not randomised.<BR/>Funding: NS.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>NS: not stated; SD: standard deviation; SE: standard error; h: hours.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brunati-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract, N = 55, not stated it was a randomised trial. Author did not reply to our letter.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-D_x0027_Amico-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prophylactic study (prevention of rebleeding after control of acute bleeding).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jenkins-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerns long-term prevention of rebleeding in fully stable patients; does not address the control of acute bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Primignani-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data on acute bleeding, concerns rebleeding in stable patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ruiz-del-Arbol-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Small trial (N = 15 to 20 per group), no clinical outcomes but haemodynamic variables up to 15 minutes after drug administration.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shields-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerns long-term prevention of rebleeding in fully stable patients; does not address the control of acute bleeding.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silva-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not fully randomised. Because of a high rate of rebleeding in the octreotide arm, only 13 patients received this drug, whereas randomisation continued in the two other arms.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-UCB-trial-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerns early rebleeding. Unpublished trial, about 150 patients. The sponsoring company, UCB Pharma, Belgium, has refused to give access to data, and the investigators are unable to publish as they signed a contract stating that the results belong to the company.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Avgerinos-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Besson-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Burroughs-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Burroughs-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cal_x00e8_s-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Farooqi-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Freitas-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-G_x00f8_tzsche-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Isaac-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Morales-2007">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Moret_x00f3_-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Pauwels-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Shah-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Shiha-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Signorelli-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Signorelli-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Souza-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sung-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Valenzuela-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Villanueva-2001">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Zuberi-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-01-11 10:21:25 +0100" MODIFIED_BY="dimitrinka nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2012-01-11 10:21:25 +0100" MODIFIED_BY="dimitrinka nikolova" NO="1">
<NAME>Somatostatin analogues versus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="9.260620391448969" CI_END="1.0403998213365735" CI_START="0.7357518048869288" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8749148794896692" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="214" I2="0.0" I2_Q="14.57878795623258" ID="CMP-001.01" LOG_CI_END="0.017200268944301374" LOG_CI_START="-0.13326866385088326" LOG_EFFECT_SIZE="-0.05803419745329092" METHOD="MH" NO="1" P_CHI2="0.8635008495467187" P_Q="0.27926378967489873" P_Z="0.13056624675953207" Q="1.170669411114921" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1090" TOTAL_2="1085" WEIGHT="100.0" Z="1.5118727137510002">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.433933453083067" CI_END="1.2473352617472075" CI_START="0.7520435206862327" DF="7" EFFECT_SIZE="0.9685300210734067" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="96" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.09598319987580142" LOG_CI_START="-0.12375702610120962" LOG_EFFECT_SIZE="-0.013886913112704093" NO="1" P_CHI2="0.8421729454405481" P_Z="0.8043452452061588" STUDIES="8" TAU2="0.0" TOTAL_1="519" TOTAL_2="516" WEIGHT="44.625647171868714" Z="0.2477275103938825">
<NAME>Randomisation concealed, double-blind trials</NAME>
<DICH_DATA CI_END="1.8661587981154861" CI_START="0.7190852479372388" EFFECT_SIZE="1.1584158415841583" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.27094859665108334" LOG_CI_START="-0.14321962072404526" LOG_EFFECT_SIZE="0.06386448796351904" ORDER="725" O_E="0.0" SE="0.24328446105189122" STUDY_ID="STD-Avgerinos-1997" TOTAL_1="101" TOTAL_2="104" VAR="0.05918732898930918" WEIGHT="11.026355629481225"/>
<DICH_DATA CI_END="2.1825483939802184" CI_START="0.4866611903145905" EFFECT_SIZE="1.030612244897959" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.3389638821625124" LOG_CI_START="-0.312773285982217" LOG_EFFECT_SIZE="0.013095298090147684" ORDER="726" O_E="0.0" SE="0.38283363871922704" STUDY_ID="STD-Besson-1995" TOTAL_1="98" TOTAL_2="101" VAR="0.14656159493500368" WEIGHT="5.510709104837997"/>
<DICH_DATA CI_END="3.122359240709632" CI_START="0.49527958041502373" EFFECT_SIZE="1.243559718969555" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.49448286902824273" LOG_CI_START="-0.3051495769153523" LOG_EFFECT_SIZE="0.09466664605644522" ORDER="727" O_E="0.0" SE="0.4697080569917129" STUDY_ID="STD-Burroughs-1990" TOTAL_1="61" TOTAL_2="59" VAR="0.22062565880293025" WEIGHT="3.3181794555371256"/>
<DICH_DATA CI_END="1.2530459943779104" CI_START="0.4107650625050459" EFFECT_SIZE="0.7174311926605504" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="25" LOG_CI_END="0.09796701252480995" LOG_CI_START="-0.3864065022863613" LOG_EFFECT_SIZE="-0.14421974488077563" ORDER="728" O_E="0.0" SE="0.2845234002876497" STUDY_ID="STD-Cal_x00e8_s-2001" TOTAL_1="109" TOTAL_2="115" VAR="0.08095356531124615" WEIGHT="11.344143964961527"/>
<DICH_DATA CI_END="1.813994092001863" CI_START="0.6050216336278528" EFFECT_SIZE="1.0476190476190477" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.25863586827249524" LOG_CI_START="-0.21822909609592123" LOG_EFFECT_SIZE="0.02020338608828699" ORDER="729" O_E="0.0" SE="0.2801128405896514" STUDY_ID="STD-G_x00f8_tzsche-1995" TOTAL_1="42" TOTAL_2="44" VAR="0.07846320346320346" WEIGHT="7.286585460882136"/>
<DICH_DATA CI_END="3.067678867090118" CI_START="0.40890851172759024" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.48680989453694445" LOG_CI_START="-0.3883738491965812" LOG_EFFECT_SIZE="0.04921802267018165" ORDER="730" O_E="0.0" SE="0.5140872632984738" STUDY_ID="STD-Morales-2007" TOTAL_1="40" TOTAL_2="28" VAR="0.2642857142857143" WEIGHT="2.742674849596743"/>
<DICH_DATA CI_END="1.6590617577333566" CI_START="0.12453518941344939" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.21986255271731162" LOG_CI_START="-0.9047079143617242" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="731" O_E="0.0" SE="0.6605782590758164" STUDY_ID="STD-Moret_x00f3_-1994" TOTAL_1="33" TOTAL_2="30" VAR="0.4363636363636364" WEIGHT="2.9307439821405192"/>
<DICH_DATA CI_END="15.362407364476699" CI_START="0.06509396452487991" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1864592771008313" LOG_CI_START="-1.1864592771008313" LOG_EFFECT_SIZE="0.0" ORDER="732" O_E="0.0" SE="1.3938641048743392" STUDY_ID="STD-Zuberi-2000" TOTAL_1="35" TOTAL_2="35" VAR="1.942857142857143" WEIGHT="0.4662547244314462"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.905662109356475" CI_END="1.0145204923420454" CI_START="0.6300064455862142" DF="7" EFFECT_SIZE="0.7994713561815633" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="118" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.006260823790447282" LOG_CI_START="-0.2006550072635521" LOG_EFFECT_SIZE="-0.09719709173655243" NO="2" P_CHI2="0.6714747817653619" P_Z="0.0655694831137815" STUDIES="8" TAU2="0.0" TOTAL_1="571" TOTAL_2="569" WEIGHT="55.374352828131286" Z="1.8413554751735013">
<NAME>High-bias risk trials</NAME>
<DICH_DATA CI_END="1.1564621299758686" CI_START="0.5721307331206837" EFFECT_SIZE="0.8134171907756813" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="53" LOG_CI_END="0.06313141573889672" LOG_CI_START="-0.24250472263071007" LOG_EFFECT_SIZE="-0.08968665344590669" ORDER="733" O_E="0.0" SE="0.17953218060159204" STUDY_ID="STD-Burroughs-1996" TOTAL_1="189" TOTAL_2="194" VAR="0.032231803871562666" WEIGHT="24.388895951069436"/>
<DICH_DATA CI_END="1.4076116001038534" CI_START="0.02148728149841897" EFFECT_SIZE="0.17391304347826086" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14848283719152472" LOG_CI_START="-1.6678185265707857" LOG_EFFECT_SIZE="-0.7596678446896306" ORDER="734" O_E="0.0" SE="1.066904411910734" STUDY_ID="STD-Farooqi-2000" TOTAL_1="69" TOTAL_2="72" VAR="1.1382850241545894" WEIGHT="2.7380064668740247"/>
<DICH_DATA CI_END="2.7068861622348974" CI_START="0.4380232271632516" EFFECT_SIZE="1.0888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.4324699919534471" LOG_CI_START="-0.3585028594471072" LOG_EFFECT_SIZE="0.036983566253169946" ORDER="735" O_E="0.0" SE="0.4646213682914464" STUDY_ID="STD-Pauwels-1994" TOTAL_1="18" TOTAL_2="14" VAR="0.21587301587301586" WEIGHT="2.622682824926885"/>
<DICH_DATA CI_END="1.862093460086389" CI_START="0.4181029199074941" EFFECT_SIZE="0.8823529411764706" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.2700014748092209" LOG_CI_START="-0.3787167994544063" LOG_EFFECT_SIZE="-0.0543576623225927" ORDER="736" O_E="0.0" SE="0.38106032550970187" STUDY_ID="STD-Shah-1996" TOTAL_1="51" TOTAL_2="54" VAR="0.14520697167755994" WEIGHT="5.4351979305151445"/>
<DICH_DATA CI_END="2.390938187205628" CI_START="0.3412120237176184" EFFECT_SIZE="0.9032258064516129" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.37856834846938653" LOG_CI_START="-0.46697567345349356" LOG_EFFECT_SIZE="-0.04420366249205347" ORDER="737" O_E="0.0" SE="0.4966767439879113" STUDY_ID="STD-Shiha-1996" TOTAL_1="93" TOTAL_2="96" VAR="0.2466877880184332" WEIGHT="3.6708308463174175"/>
<DICH_DATA CI_END="1.6066419615470497" CI_START="0.3682936151882853" EFFECT_SIZE="0.7692307692307693" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.2059191054820821" LOG_CI_START="-0.4338058100957556" LOG_EFFECT_SIZE="-0.11394335230683675" ORDER="738" O_E="0.0" SE="0.3757775820998257" STUDY_ID="STD-Souza-2003" TOTAL_1="56" TOTAL_2="56" VAR="0.14120879120879123" WEIGHT="6.061311417608801"/>
<DICH_DATA CI_END="1.2071919239845728" CI_START="0.1711505570431353" EFFECT_SIZE="0.45454545454545453" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.08177632138261974" LOG_CI_START="-0.7666216830270323" LOG_EFFECT_SIZE="-0.3424226808222063" ORDER="739" O_E="0.0" SE="0.4983531874280822" STUDY_ID="STD-Sung-1995" TOTAL_1="47" TOTAL_2="47" VAR="0.24835589941972921" WEIGHT="5.1288019687459085"/>
<DICH_DATA CI_END="2.206066899539095" CI_START="0.5737020034453272" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.34361867839434856" LOG_CI_START="-0.24131363349958593" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="740" O_E="0.0" SE="0.3435921354681384" STUDY_ID="STD-Valenzuela-1989" TOTAL_1="48" TOTAL_2="36" VAR="0.11805555555555557" WEIGHT="5.328625422073671"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="22.06456045410738" CI_END="-0.5518076264652396" CI_START="-1.286038375505537" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9189230009853883" ESTIMABLE="YES" I2="36.54983506642272" I2_Q="78.55587653387035" ID="CMP-001.02" MODIFIED="2008-05-05 14:21:06 +0200" MODIFIED_BY="dimitrinka nikolova" NO="2" P_CHI2="0.07729759644319201" P_Q="0.030814305845983103" P_Z="9.29680607037499E-7" Q="4.66328223477854" RANDOM="YES" SCALE="8.164991863343696" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.16199042522062593" TOTALS="YES" TOTAL_1="845" TOTAL_2="812" UNITS="" WEIGHT="100.0" Z="4.905967201321822">
<NAME>Number of transfusions</NAME>
<GROUP_LABEL_1>Drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="15.089156654080883" CI_END="-0.20605509138047412" CI_START="-1.1287761153067157" DF="8" EFFECT_SIZE="-0.667415603343595" ESTIMABLE="YES" I2="46.98179505057767" ID="CMP-001.02.01" NO="1" P_CHI2="0.05743490636582549" P_Z="0.004577798498941829" STUDIES="9" TAU2="0.1975286730679184" TOTAL_1="593" TOTAL_2="580" WEIGHT="69.9903176625114" Z="2.8353326983001126">
<NAME>Randomisation concealed, double-blind trials</NAME>
<CONT_DATA CI_END="0.20881046666681558" CI_START="-2.0088104666668163" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.7" ORDER="741" SD_1="4.0" SD_2="4.1" SE="0.5657300212723149" STUDY_ID="STD-Avgerinos-1997" TOTAL_1="101" TOTAL_2="104" WEIGHT="7.278218526272317"/>
<CONT_DATA CI_END="-0.6441841846644344" CI_START="-1.755815815335565" EFFECT_SIZE="-1.1999999999999997" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.8" ORDER="742" SD_1="2.0" SD_2="2.0" SE="0.28358470855575385" STUDY_ID="STD-Besson-1995" TOTAL_1="98" TOTAL_2="101" WEIGHT="14.47295314672396"/>
<CONT_DATA CI_END="-0.970771984225582" CI_START="-5.029228015774418" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="6.0" ORDER="743" SD_1="5.67" SD_2="5.67" SE="1.0353394408166219" STUDY_ID="STD-Burroughs-1990" TOTAL_1="61" TOTAL_2="59" WEIGHT="2.8432994405168275"/>
<CONT_DATA CI_END="0.3220771046611075" CI_START="-1.7220771046611079" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="2.8" MEAN_2="3.5" ORDER="744" SD_1="3.6" SD_2="3.7" SE="0.5214774928126851" STUDY_ID="STD-Cal_x00e8_s-2001" TOTAL_1="98" TOTAL_2="98" WEIGHT="8.085187337617848"/>
<CONT_DATA CI_END="6.850572495574973" CI_START="-0.8505724955749732" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="8.0" MEAN_2="5.0" ORDER="745" SD_1="7.8" SD_2="10.3" SE="1.9646139041062987" STUDY_ID="STD-G_x00f8_tzsche-1995" TOTAL_1="42" TOTAL_2="44" WEIGHT="0.8723675147895369"/>
<CONT_DATA CI_END="1.148374572077143" CI_START="-1.2083745720771435" EFFECT_SIZE="-0.03000000000000025" ESTIMABLE="YES" MEAN_1="2.05" MEAN_2="2.08" ORDER="746" SD_1="2.44" SD_2="2.44" SE="0.601222563971589" STUDY_ID="STD-Morales-2007" TOTAL_1="40" TOTAL_2="28" WEIGHT="6.7023375309809365"/>
<CONT_DATA CI_END="0.7177600248113969" CI_START="-1.237760024811397" EFFECT_SIZE="-0.26" ESTIMABLE="YES" MEAN_1="1.14" MEAN_2="1.4" ORDER="747" SD_1="2.9" SD_2="3.9" SE="0.4988663223017582" STUDY_ID="STD-Shiha-1996" TOTAL_1="93" TOTAL_2="96" WEIGHT="8.539199917085769"/>
<CONT_DATA CI_END="1.532607203412546" CI_START="-1.3326072034125458" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.2" MEAN_2="3.1" ORDER="748" SD_1="2.3" SD_2="2.2" SE="0.7309354736682758" STUDY_ID="STD-Villanueva-2001" TOTAL_1="25" TOTAL_2="15" WEIGHT="5.038941678369958"/>
<CONT_DATA CI_END="-0.1397511380028142" CI_START="-1.060248861997186" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="2.1" ORDER="749" SD_1="0.7" SD_2="1.2" SE="0.23482516292522218" STUDY_ID="STD-Zuberi-2000" TOTAL_1="35" TOTAL_2="35" WEIGHT="16.157812570154253"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.6054598067653942" CI_END="-0.9064182552433051" CI_START="-2.032097584081107" DF="5" EFFECT_SIZE="-1.469257919662206" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.02" NO="2" P_CHI2="0.9005883571551075" P_Z="3.114816580224268E-7" STUDIES="6" TAU2="0.0" TOTAL_1="252" TOTAL_2="232" WEIGHT="30.0096823374886" Z="5.116364017293065">
<NAME>High-bias risk trials</NAME>
<CONT_DATA CI_END="-0.5201613103438334" CI_START="-3.479838689656167" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="2.9" ORDER="750" SD_1="3.5" SD_2="3.5" SE="0.7550336135403228" STUDY_ID="STD-Freitas-2000" TOTAL_1="44" TOTAL_2="42" WEIGHT="4.79246133972475"/>
<CONT_DATA CI_END="0.22807910035588952" CI_START="-3.828079100355889" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="5.3" ORDER="751" SD_1="2.1" SD_2="3.4" SE="1.0347532487092204" STUDY_ID="STD-Pauwels-1994" TOTAL_1="18" TOTAL_2="14" WEIGHT="2.8460983786706624"/>
<CONT_DATA CI_END="-0.3333151470386655" CI_START="-2.646684852961335" EFFECT_SIZE="-1.4900000000000002" ESTIMABLE="YES" MEAN_1="3.88" MEAN_2="5.37" ORDER="752" SD_1="2.8" SD_2="3.15" SE="0.5901561774017876" STUDY_ID="STD-Shah-1996" TOTAL_1="51" TOTAL_2="51" WEIGHT="6.875509625300145"/>
<CONT_DATA CI_END="-0.4790275816507159" CI_START="-2.8809724183492844" EFFECT_SIZE="-1.6800000000000002" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="3.96" ORDER="753" SD_1="2.1" SD_2="3.4" SE="0.61275228923715" STUDY_ID="STD-Signorelli-1997" TOTAL_1="44" TOTAL_2="42" WEIGHT="6.527790608366203"/>
<CONT_DATA CI_END="0.03098973273389327" CI_START="-2.030989732733893" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="4.0" ORDER="754" SD_1="2.55" SD_2="2.55" SE="0.5260248355919847" STUDY_ID="STD-Sung-1995" TOTAL_1="47" TOTAL_2="47" WEIGHT="7.997397849900646"/>
<CONT_DATA CI_END="2.742229783268813" CI_START="-4.542229783268812" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="4.6" ORDER="755" SD_1="7.6" SD_2="9.0" SE="1.8583146486355138" STUDY_ID="STD-Valenzuela-1989" TOTAL_1="48" TOTAL_2="36" WEIGHT="0.970424535526194"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="10.11583187130072" CI_END="1.2945548490509826" CI_START="0.40536435275544497" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7244076121162548" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="53" I2="40.68703319375647" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.1121204558025968" LOG_CI_START="-0.39215444528852833" LOG_EFFECT_SIZE="-0.14001699474296578" METHOD="MH" NO="3" P_CHI2="0.11985817703191914" P_Q="0.5165472935282702" P_Z="0.27641531274936015" Q="0.420781645589909" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.2245282021653935" TOTALS="YES" TOTAL_1="407" TOTAL_2="397" WEIGHT="100.0" Z="1.0884073997177044">
<NAME>Number with balloon tamponade</NAME>
<GROUP_LABEL_1>Drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.293783439162768" CI_END="1.4017620932318728" CI_START="0.48598859283004336" DF="4" EFFECT_SIZE="0.8253728776572767" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="40" I2="24.43967446026437" ID="CMP-001.03.01" LOG_CI_END="0.14667431151653934" LOG_CI_START="-0.31337392441899686" LOG_EFFECT_SIZE="-0.08334980645122876" NO="1" P_CHI2="0.2584595831592179" P_Z="0.47758150023420787" STUDIES="5" TAU2="0.08935128510370872" TOTAL_1="342" TOTAL_2="336" WEIGHT="80.26900106379648" Z="0.7101977836327739">
<NAME>Randomisation concealed, double-blind trials</NAME>
<DICH_DATA CI_END="1.6594238231944316" CI_START="0.11735809189649697" EFFECT_SIZE="0.44130127298444133" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2199573206640885" LOG_CI_START="-0.9304869602210015" LOG_EFFECT_SIZE="-0.3552648197784566" ORDER="756" O_E="0.0" SE="0.6757766653829367" STUDY_ID="STD-Avgerinos-1997" TOTAL_1="101" TOTAL_2="104" VAR="0.4566741014760816" WEIGHT="12.88053202709096"/>
<DICH_DATA CI_END="2.98048722586188" CI_START="0.22807795238140482" EFFECT_SIZE="0.8244897959183674" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.47428726481686856" LOG_CI_START="-0.6419166946526859" LOG_EFFECT_SIZE="-0.08381471491790869" ORDER="757" O_E="0.0" SE="0.6556637310911265" STUDY_ID="STD-Besson-1995" TOTAL_1="98" TOTAL_2="101" VAR="0.42989492826833703" WEIGHT="13.407606915065598"/>
<DICH_DATA CI_END="1.1251583216099628" CI_START="0.23649838130386333" EFFECT_SIZE="0.5158469945355191" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="0.05121363654857674" LOG_CI_START="-0.6261718274132978" LOG_EFFECT_SIZE="-0.28747909543236055" ORDER="758" O_E="0.0" SE="0.39789957464333003" STUDY_ID="STD-Burroughs-1990" TOTAL_1="61" TOTAL_2="59" VAR="0.15832407150134295" WEIGHT="22.918103645950733"/>
<DICH_DATA CI_END="2.343164849995848" CI_START="0.7095078241570891" EFFECT_SIZE="1.2893772893772895" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.36980284383599504" LOG_CI_START="-0.14904281096124505" LOG_EFFECT_SIZE="0.110380016437375" ORDER="759" O_E="0.0" SE="0.3047725059553115" STUDY_ID="STD-G_x00f8_tzsche-1995" TOTAL_1="42" TOTAL_2="44" VAR="0.09288628038628038" WEIGHT="27.642872557189467"/>
<DICH_DATA CI_END="70.95543209289069" CI_START="0.1762717198818021" EFFECT_SIZE="3.5365853658536586" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8509856490910563" LOG_CI_START="-0.7538173580605774" LOG_EFFECT_SIZE="0.5485841455152394" ORDER="760" O_E="0.0" SE="1.5300741803837066" STUDY_ID="STD-Morales-2007" TOTAL_1="40" TOTAL_2="28" VAR="2.3411269974768714" WEIGHT="3.419885918499716"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.168778041638973" CI_END="4.1741509779835635" CI_START="0.031044265030362308" DF="1" EFFECT_SIZE="0.35997701209558886" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" I2="76.01215536035481" ID="CMP-001.03.02" LOG_CI_END="0.620568153334929" LOG_CI_START="-1.508018617571466" LOG_EFFECT_SIZE="-0.44372523211826864" NO="2" P_CHI2="0.0411756132502038" P_Z="0.41384372161837046" STUDIES="2" TAU2="2.39844178570423" TOTAL_1="65" TOTAL_2="61" WEIGHT="19.730998936203523" Z="0.8171482467807998">
<NAME>High-bias risk trials</NAME>
<DICH_DATA CI_END="3.89773001900941" CI_START="0.27591593336161235" EFFECT_SIZE="1.037037037037037" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.5908117538900908" LOG_CI_START="-0.5592232195236271" LOG_EFFECT_SIZE="0.015794267183231882" ORDER="761" O_E="0.0" SE="0.675536236148148" STUDY_ID="STD-Pauwels-1994" TOTAL_1="18" TOTAL_2="14" VAR="0.4563492063492063" WEIGHT="12.88667824671116"/>
<DICH_DATA CI_END="0.7504289014652682" CI_START="0.01332571277635265" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.12469044820951244" LOG_CI_START="-1.8753095517904872" LOG_EFFECT_SIZE="-1.0" ORDER="762" O_E="0.0" SE="1.0283223271477862" STUDY_ID="STD-Sung-1995" TOTAL_1="47" TOTAL_2="47" VAR="1.0574468085106385" WEIGHT="6.844320689492363"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="39.0218859889544" CI_END="0.8661209898978497" CI_START="0.5413991642848262" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6847752770801836" ESTIMABLE="YES" EVENTS_1="257" EVENTS_2="353" I2="58.99736879829697" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.06242143641826026" LOG_CI_START="-0.2664824189511211" LOG_EFFECT_SIZE="-0.16445192768469066" METHOD="MH" MODIFIED="2012-01-11 10:21:25 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="4" P_CHI2="0.001079735678659377" P_Q="0.8608543537164426" P_Z="0.0015828203245000913" Q="0.030725447856220483" RANDOM="YES" SCALE="16.95744760501986" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.10843947197341847" TOTALS="YES" TOTAL_1="979" TOTAL_2="953" WEIGHT="100.0" Z="3.1590542341750663">
<NAME>Number failing initial haemostasis</NAME>
<GROUP_LABEL_1>Drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="19.849612171208065" CI_END="0.8987680192070995" CI_START="0.49291124417700644" DF="8" EFFECT_SIZE="0.6655921142665941" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="207" I2="59.69694555743497" ID="CMP-001.04.01" LOG_CI_END="-0.04635238944492886" LOG_CI_START="-0.3072312747072583" LOG_EFFECT_SIZE="-0.1767918320760936" NO="1" P_CHI2="0.010920261271398779" P_Z="0.007896857997855368" STUDIES="9" TAU2="0.10564068287632687" TOTAL_1="533" TOTAL_2="514" WEIGHT="60.195656124113626" Z="2.6564482079993885">
<NAME>Randomisation concealed, double-blind trials</NAME>
<DICH_DATA CI_END="0.8704204568095237" CI_START="0.45928389720071866" EFFECT_SIZE="0.6322737536911586" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="57" LOG_CI_END="-0.0602709106432614" LOG_CI_START="-0.3379187809688946" LOG_EFFECT_SIZE="-0.19909484580607797" ORDER="763" O_E="0.0" SE="0.16309173340840072" STUDY_ID="STD-Avgerinos-1997" TOTAL_1="101" TOTAL_2="104" VAR="0.026598913506156854" WEIGHT="10.63990900919924"/>
<DICH_DATA CI_END="0.6898721561772131" CI_START="0.06158599617757379" EFFECT_SIZE="0.20612244897959184" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="15" LOG_CI_END="-0.1612313831917128" LOG_CI_START="-1.2105180293000295" LOG_EFFECT_SIZE="-0.6858747062458711" ORDER="764" O_E="0.0" SE="0.6163561699766921" STUDY_ID="STD-Besson-1995" TOTAL_1="98" TOTAL_2="101" VAR="0.379894928268337" WEIGHT="2.942238215330624"/>
<DICH_DATA CI_END="0.902745216597327" CI_START="0.4094382669724128" EFFECT_SIZE="0.6079625292740047" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" LOG_CI_END="-0.04443480410400413" LOG_CI_START="-0.38781156968938035" LOG_EFFECT_SIZE="-0.2161231868966922" ORDER="765" O_E="0.0" SE="0.20170121184725273" STUDY_ID="STD-Burroughs-1990" TOTAL_1="61" TOTAL_2="59" VAR="0.04068337886065032" WEIGHT="9.63498301042137"/>
<DICH_DATA CI_END="0.8562224454904748" CI_START="0.38988368297516307" EFFECT_SIZE="0.5777777777777777" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="45" LOG_CI_END="-0.0674133915158573" LOG_CI_START="-0.40906494009319416" LOG_EFFECT_SIZE="-0.23823916580452575" ORDER="766" O_E="0.0" SE="0.20068781083676848" STUDY_ID="STD-Cal_x00e8_s-2001" TOTAL_1="98" TOTAL_2="98" VAR="0.04027559741845457" WEIGHT="9.661402439760895"/>
<DICH_DATA CI_END="2.0981603195533314" CI_START="0.9533132730574508" EFFECT_SIZE="1.4142857142857144" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="20" LOG_CI_END="0.3218386693853" LOG_CI_START="-0.020764360218713748" LOG_EFFECT_SIZE="0.15053715458329311" ORDER="767" O_E="0.0" SE="0.20124671550174553" STUDY_ID="STD-G_x00f8_tzsche-1995" TOTAL_1="42" TOTAL_2="44" VAR="0.0405002405002405" WEIGHT="9.646830320731018"/>
<DICH_DATA CI_END="2.3938834530405875" CI_START="0.36389035982711293" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3791030028233342" LOG_CI_START="-0.4390294495782207" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="768" O_E="0.0" SE="0.4805750523616274" STUDY_ID="STD-Morales-2007" TOTAL_1="40" TOTAL_2="28" VAR="0.2309523809523809" WEIGHT="4.233443206917454"/>
<DICH_DATA CI_END="0.972650526244584" CI_START="0.3389324053710113" EFFECT_SIZE="0.5741626794258373" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="19" LOG_CI_END="-0.012043173900824013" LOG_CI_START="-0.46988690622603435" LOG_EFFECT_SIZE="-0.24096504006342917" ORDER="769" O_E="0.0" SE="0.268939674730855" STUDY_ID="STD-Moret_x00f3_-1994" TOTAL_1="33" TOTAL_2="30" VAR="0.0723285486443381" WEIGHT="7.948287143609508"/>
<DICH_DATA CI_END="1.734459588262987" CI_START="0.2075574446565976" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.239164185527836" LOG_CI_START="-0.6828616847605488" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="770" O_E="0.0" SE="0.5416025603090641" STUDY_ID="STD-Villanueva-2001" TOTAL_1="25" TOTAL_2="15" VAR="0.2933333333333334" WEIGHT="3.5761408320179"/>
<DICH_DATA CI_END="1.9254823233911804" CI_START="0.08309606276634432" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2845395360000861" LOG_CI_START="-1.0804195533441612" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="771" O_E="0.0" SE="0.8017837257372731" STUDY_ID="STD-Zuberi-2000" TOTAL_1="35" TOTAL_2="35" VAR="0.6428571428571428" WEIGHT="1.912421946125621"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.582505784103953" CI_END="1.060368449576624" CI_START="0.45818519435345195" DF="7" EFFECT_SIZE="0.6970259135466442" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="146" I2="55.07782832244574" ID="CMP-001.04.02" LOG_CI_END="0.02545679716495943" LOG_CI_START="-0.3389589485697648" LOG_EFFECT_SIZE="-0.15675107570240265" NO="2" P_CHI2="0.029216737072838228" P_Z="0.09177044341864721" STUDIES="8" TAU2="0.16973693359277248" TOTAL_1="446" TOTAL_2="439" WEIGHT="39.80434387588638" Z="1.6861316587470718">
<NAME>High-bias risk trials</NAME>
<DICH_DATA CI_END="1.1828374774221682" CI_START="0.786311862694297" EFFECT_SIZE="0.9644061074757089" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="82" LOG_CI_END="0.0729250764051368" LOG_CI_START="-0.10440517230040199" LOG_EFFECT_SIZE="-0.01574004794763258" ORDER="772" O_E="0.0" SE="0.10416466588852154" STUDY_ID="STD-Burroughs-1996" TOTAL_1="123" TOTAL_2="137" VAR="0.010850277619667321" WEIGHT="12.044590077127062"/>
<DICH_DATA CI_END="0.8970148338494272" CI_START="0.07615364633389086" EFFECT_SIZE="0.26136363636363635" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.04720037500977214" LOG_CI_START="-1.1183092972553792" LOG_EFFECT_SIZE="-0.5827548361325758" ORDER="773" O_E="0.0" SE="0.6291746830017455" STUDY_ID="STD-Farooqi-2000" TOTAL_1="72" TOTAL_2="69" VAR="0.3958607817303469" WEIGHT="2.849088660375436"/>
<DICH_DATA CI_END="0.9664760985921942" CI_START="0.22383704405191696" EFFECT_SIZE="0.46511627906976744" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="-0.0148088818091198" LOG_CI_START="-0.6500680380220908" LOG_EFFECT_SIZE="-0.33243845991560533" ORDER="774" O_E="0.0" SE="0.37315437294303766" STUDY_ID="STD-Freitas-2000" TOTAL_1="43" TOTAL_2="40" VAR="0.13924418604651165" WEIGHT="5.8009323091321585"/>
<DICH_DATA CI_END="1.4890160080048518" CI_START="0.18056317232404337" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.17289936675875958" LOG_CI_START="-0.7433708237202582" LOG_EFFECT_SIZE="-0.2852357284807493" ORDER="775" O_E="0.0" SE="0.5382216454979674" STUDY_ID="STD-Pauwels-1994" TOTAL_1="18" TOTAL_2="14" VAR="0.28968253968253965" WEIGHT="3.6089341764239795"/>
<DICH_DATA CI_END="1.4433909623473316" CI_START="0.1941794177186707" EFFECT_SIZE="0.5294117647058824" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.15938398167744583" LOG_CI_START="-0.7117968055553439" LOG_EFFECT_SIZE="-0.27620641193894907" ORDER="776" O_E="0.0" SE="0.5117359068349872" STUDY_ID="STD-Shah-1996" TOTAL_1="51" TOTAL_2="54" VAR="0.2618736383442266" WEIGHT="3.8799494109711814"/>
<DICH_DATA CI_END="1.2779093836261217" CI_START="0.24262008838493365" EFFECT_SIZE="0.5568181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="12" LOG_CI_END="0.10650005915382697" LOG_CI_START="-0.615073243397137" LOG_EFFECT_SIZE="-0.254286592121655" ORDER="777" O_E="0.0" SE="0.42385572976388985" STUDY_ID="STD-Signorelli-1997" TOTAL_1="44" TOTAL_2="42" VAR="0.17965367965367962" WEIGHT="4.987262370303106"/>
<DICH_DATA CI_END="3.8093132820984206" CI_START="0.11667311442539456" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5808466909837985" LOG_CI_START="-0.9330292090951611" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="778" O_E="0.0" SE="0.8892581975129448" STUDY_ID="STD-Sung-1995" TOTAL_1="47" TOTAL_2="47" VAR="0.7907801418439715" WEIGHT="1.5978256169839642"/>
<DICH_DATA CI_END="4.845613013465133" CI_START="0.9318996352890435" EFFECT_SIZE="2.125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="6" LOG_CI_END="0.6853487270058538" LOG_CI_START="-0.030630858233193076" LOG_EFFECT_SIZE="0.32735893438633035" ORDER="779" O_E="0.0" SE="0.4205699525255225" STUDY_ID="STD-Valenzuela-1989" TOTAL_1="48" TOTAL_2="36" VAR="0.17687908496732024" WEIGHT="5.035761254569498"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="29.44566419088993" CI_END="0.907838244222909" CI_START="0.4168986341806503" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6152044571307091" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="171" I2="59.24697122738828" I2_Q="76.65841856208678" ID="CMP-001.05" LOG_CI_END="-0.041991525817533314" LOG_CI_START="-0.3799695276819983" LOG_EFFECT_SIZE="-0.21098052674976578" METHOD="MH" NO="5" P_CHI2="0.003381565539696152" P_Q="0.03846835896803791" P_Z="0.01440552178346271" Q="4.284199863063784" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.26606704176509605" TOTALS="SUB" TOTAL_1="694" TOTAL_2="669" WEIGHT="199.99999999999997" Z="2.446989044184342">
<NAME>Number with rebleeding</NAME>
<GROUP_LABEL_1>Drug</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours drug</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.607840969098431" CI_END="1.3697917403472886" CI_START="0.5156178187884002" DF="5" EFFECT_SIZE="0.8404100364418762" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="72" I2="47.95917192966211" ID="CMP-001.05.01" LOG_CI_END="0.1366545431467582" LOG_CI_START="-0.2876720826534696" LOG_EFFECT_SIZE="-0.07550876975335567" NO="1" P_CHI2="0.08714084431873903" P_Z="0.4854588113183199" STUDIES="6" TAU2="0.1622449958796729" TOTAL_1="309" TOTAL_2="297" WEIGHT="99.99999999999999" Z="0.697549765840902">
<NAME>Randomisation concealed, double-blind trials</NAME>
<DICH_DATA CI_END="2.0020936847767405" CI_START="0.33953627082606563" EFFECT_SIZE="0.8244897959183674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.3014843957355203" LOG_CI_START="-0.46911382557133774" LOG_EFFECT_SIZE="-0.08381471491790869" ORDER="780" O_E="0.0" SE="0.45265320971836376" STUDY_ID="STD-Besson-1995" TOTAL_1="98" TOTAL_2="101" VAR="0.20489492826833702" WEIGHT="16.921706493457844"/>
<DICH_DATA CI_END="0.9083311611011567" CI_START="0.44577218285109915" EFFECT_SIZE="0.6363244176013805" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="38" LOG_CI_END="-0.04175578670102953" LOG_CI_START="-0.3508870359257613" LOG_EFFECT_SIZE="-0.1963214113133954" ORDER="781" O_E="0.0" SE="0.18158522601897026" STUDY_ID="STD-Burroughs-1990" TOTAL_1="61" TOTAL_2="59" VAR="0.032973194308360515" WEIGHT="31.824053037675508"/>
<DICH_DATA CI_END="4.675858744133709" CI_START="0.9388698239108796" EFFECT_SIZE="2.0952380952380953" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6698613828213067" LOG_CI_START="-0.027394619316770324" LOG_EFFECT_SIZE="0.3212333817522682" ORDER="782" O_E="0.0" SE="0.40957162712878165" STUDY_ID="STD-G_x00f8_tzsche-1995" TOTAL_1="42" TOTAL_2="44" VAR="0.16774891774891773" WEIGHT="18.826510980609605"/>
<DICH_DATA CI_END="2.3938834530405875" CI_START="0.36389035982711293" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.3791030028233342" LOG_CI_START="-0.4390294495782207" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="783" O_E="0.0" SE="0.4805750523616274" STUDY_ID="STD-Morales-2007" TOTAL_1="40" TOTAL_2="28" VAR="0.2309523809523809" WEIGHT="15.80029370622327"/>
<DICH_DATA CI_END="4.164933703007989" CI_START="0.19842963656176835" EFFECT_SIZE="0.9090909090909091" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6196080927423374" LOG_CI_START="-0.7023934630587876" LOG_EFFECT_SIZE="-0.04139268515822506" ORDER="784" O_E="0.0" SE="0.7765502578908225" STUDY_ID="STD-Moret_x00f3_-1994" TOTAL_1="33" TOTAL_2="30" VAR="0.603030303030303" WEIGHT="8.118168778362504"/>
<DICH_DATA CI_END="1.0948987696563037" CI_START="0.05708290275969458" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.039373967749679495" LOG_CI_START="-1.2434939504056042" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="785" O_E="0.0" SE="0.7535629654230248" STUDY_ID="STD-Zuberi-2000" TOTAL_1="35" TOTAL_2="35" VAR="0.5678571428571428" WEIGHT="8.509267003671255"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.383315282781176" CI_END="0.6814213087443349" CI_START="0.18812006416155302" DF="6" EFFECT_SIZE="0.35803494287853205" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="99" I2="55.16805908533342" ID="CMP-001.05.02" LOG_CI_END="-0.16658428972120248" LOG_CI_START="-0.7255648818024004" LOG_EFFECT_SIZE="-0.4460745857618015" NO="2" P_CHI2="0.03733704272652394" P_Z="0.00175904914011273" STUDIES="7" TAU2="0.36166288464888613" TOTAL_1="385" TOTAL_2="372" WEIGHT="99.99999999999999" Z="3.128159134314826">
<NAME>High-bias risk trials</NAME>
<DICH_DATA CI_END="0.6295548878229162" CI_START="0.03452811545614245" EFFECT_SIZE="0.14743589743589744" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="13" LOG_CI_END="-0.20096639988582599" LOG_CI_START="-1.4618271247879115" LOG_EFFECT_SIZE="-0.8313967623368688" ORDER="786" O_E="0.0" SE="0.7406358311687328" STUDY_ID="STD-Farooqi-2000" TOTAL_1="72" TOTAL_2="69" VAR="0.5485414344109997" WEIGHT="11.844855603909487"/>
<DICH_DATA CI_END="76.17133879718433" CI_START="0.20456142293903762" EFFECT_SIZE="3.9473684210526314" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8817915888757772" LOG_CI_START="-0.6891762639980351" LOG_EFFECT_SIZE="0.596307662438871" ORDER="787" O_E="0.0" SE="1.5101992432741993" STUDY_ID="STD-Pauwels-1994" TOTAL_1="18" TOTAL_2="14" VAR="2.2807017543859645" WEIGHT="4.080147974299663"/>
<DICH_DATA CI_END="1.1880899789558894" CI_START="0.05897634471576553" EFFECT_SIZE="0.2647058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.07484933280363251" LOG_CI_START="-1.229322148009493" LOG_EFFECT_SIZE="-0.5772364076029303" ORDER="788" O_E="0.0" SE="0.766076783582577" STUDY_ID="STD-Shah-1996" TOTAL_1="51" TOTAL_2="54" VAR="0.5868736383442266" WEIGHT="11.366181973993838"/>
<DICH_DATA CI_END="0.4768057406014871" CI_START="0.06207726759227123" EFFECT_SIZE="0.17204301075268819" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.32165852445796167" LOG_CI_START="-1.207067407338059" LOG_EFFECT_SIZE="-0.7643629658980103" ORDER="789" O_E="0.0" SE="0.520093560648425" STUDY_ID="STD-Shiha-1996" TOTAL_1="93" TOTAL_2="96" VAR="0.270497311827957" WEIGHT="17.05459911807978"/>
<DICH_DATA CI_END="0.8814704964349188" CI_START="0.3760724691103894" EFFECT_SIZE="0.5757575757575758" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="33" LOG_CI_END="-0.054792219326024766" LOG_CI_START="-0.42472845852409224" LOG_EFFECT_SIZE="-0.2397603389250585" ORDER="790" O_E="0.0" SE="0.21730237811886233" STUDY_ID="STD-Souza-2003" TOTAL_1="56" TOTAL_2="56" VAR="0.04722032353611302" WEIGHT="26.36752626055785"/>
<DICH_DATA CI_END="0.6071774160914246" CI_START="0.08133160875329229" EFFECT_SIZE="0.2222222222222222" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.21668439035578574" LOG_CI_START="-1.0897406371949017" LOG_EFFECT_SIZE="-0.6532125137753437" ORDER="791" O_E="0.0" SE="0.5128375610914181" STUDY_ID="STD-Sung-1995" TOTAL_1="47" TOTAL_2="47" VAR="0.2630023640661939" WEIGHT="17.25922604386242"/>
<DICH_DATA CI_END="4.192167264376286" CI_START="0.23854010036710233" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.622438602350298" LOG_CI_START="-0.622438602350298" LOG_EFFECT_SIZE="0.0" ORDER="792" O_E="0.0" SE="0.7312470322826767" STUDY_ID="STD-Valenzuela-1989" TOTAL_1="48" TOTAL_2="36" VAR="0.5347222222222221" WEIGHT="12.02746302529695"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>